UA81216C2 - Prevention and treatment of amyloid disease - Google Patents

Prevention and treatment of amyloid disease Download PDF

Info

Publication number: UA81216C2
Authority: UA; Ukraine
Prior art keywords: amyloid; specified; component; antibody; item
Prior art date: 1999-06-01

Application number

UA2001118223A

Other languages

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-01

Filing date

2000-01-06

Publication date

2007-12-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22475417&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA81216(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-01-06 Application filed filed Critical

2007-12-25 Publication of UA81216C2 publication Critical patent/UA81216C2/uk

Links

238000011282 treatment Methods 0.000 title claims description 109
230000002265 prevention Effects 0.000 title claims description 15
206010002022 amyloidosis Diseases 0.000 title abstract description 66
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 264
108090000623 proteins and genes Proteins 0.000 claims abstract description 147
238000000034 method Methods 0.000 claims abstract description 146
102000004169 proteins and genes Human genes 0.000 claims abstract description 131
239000000203 mixture Substances 0.000 claims abstract description 123
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 107
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 60
102000001049 Amyloid Human genes 0.000 claims abstract description 10
108010094108 Amyloid Proteins 0.000 claims abstract description 10
239000002671 adjuvant Substances 0.000 claims description 114
208000037259 Amyloid Plaque Diseases 0.000 claims description 96
239000012634 fragment Substances 0.000 claims description 94
239000003795 chemical substances by application Substances 0.000 claims description 93
210000002966 serum Anatomy 0.000 claims description 82
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 70
230000028993 immune response Effects 0.000 claims description 64
201000010099 disease Diseases 0.000 claims description 49
238000009739 binding Methods 0.000 claims description 36
230000027455 binding Effects 0.000 claims description 35
238000006243 chemical reaction Methods 0.000 claims description 35
239000002243 precursor Substances 0.000 claims description 31
102000019355 Synuclein Human genes 0.000 claims description 27
108050006783 Synuclein Proteins 0.000 claims description 27
230000008105 immune reaction Effects 0.000 claims description 25
239000000523 sample Substances 0.000 claims description 22
230000003941 amyloidogenesis Effects 0.000 claims description 21
-1 "-chain of fibrogen Proteins 0.000 claims description 19
210000003719 b-lymphocyte Anatomy 0.000 claims description 19
208000035475 disorder Diseases 0.000 claims description 19
229940037003 alum Drugs 0.000 claims description 18
238000010790 dilution Methods 0.000 claims description 16
239000012895 dilution Substances 0.000 claims description 16
108010071690 Prealbumin Proteins 0.000 claims description 14
102000036770 Islet Amyloid Polypeptide Human genes 0.000 claims description 13
108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims description 13
102000009190 Transthyretin Human genes 0.000 claims description 12
102000054727 Serum Amyloid A Human genes 0.000 claims description 11
102000012192 Cystatin C Human genes 0.000 claims description 10
108010061642 Cystatin C Proteins 0.000 claims description 10
102000016943 Muramidase Human genes 0.000 claims description 10
108010014251 Muramidase Proteins 0.000 claims description 10
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 10
102000004878 Gelsolin Human genes 0.000 claims description 9
108090001064 Gelsolin Proteins 0.000 claims description 9
241000124008 Mammalia Species 0.000 claims description 9
230000007774 longterm Effects 0.000 claims description 9
239000000813 peptide hormone Substances 0.000 claims description 9
101800001288 Atrial natriuretic factor Proteins 0.000 claims description 8
101800001890 Atrial natriuretic peptide Proteins 0.000 claims description 8
102400001282 Atrial natriuretic peptide Human genes 0.000 claims description 8
102000014914 Carrier Proteins Human genes 0.000 claims description 8
108010078791 Carrier Proteins Proteins 0.000 claims description 8
108010021466 Mutant Proteins Proteins 0.000 claims description 8
102000008300 Mutant Proteins Human genes 0.000 claims description 8
NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 claims description 8
229960000274 lysozyme Drugs 0.000 claims description 8
235000010335 lysozyme Nutrition 0.000 claims description 8
239000004325 lysozyme Substances 0.000 claims description 8
102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 7
108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 7
102000011782 Keratins Human genes 0.000 claims description 7
108010076876 Keratins Proteins 0.000 claims description 7
108700028909 Serum Amyloid A Proteins 0.000 claims description 7
238000007912 intraperitoneal administration Methods 0.000 claims description 7
101100379247 Salmo trutta apoa1 gene Proteins 0.000 claims description 6
238000001990 intravenous administration Methods 0.000 claims description 6
239000000546 pharmaceutical excipient Substances 0.000 claims description 6
230000009851 immunogenic response Effects 0.000 claims description 5
150000002632 lipids Chemical class 0.000 claims description 5
238000007920 subcutaneous administration Methods 0.000 claims description 5
230000006872 improvement Effects 0.000 claims description 4
238000007918 intramuscular administration Methods 0.000 claims description 4
230000000699 topical effect Effects 0.000 claims description 4
238000004393 prognosis Methods 0.000 claims description 3
239000013068 control sample Substances 0.000 claims description 2
102000008394 Immunoglobulin Fragments Human genes 0.000 claims 4
108010021625 Immunoglobulin Fragments Proteins 0.000 claims 4
230000002797 proteolythic effect Effects 0.000 claims 2
238000011200 topical administration Methods 0.000 claims 2
102400000269 Amyloid protein A Human genes 0.000 claims 1
101710144835 Amyloid protein A Proteins 0.000 claims 1
102000018619 Apolipoproteins A Human genes 0.000 claims 1
108010027004 Apolipoproteins A Proteins 0.000 claims 1
229940124531 pharmaceutical excipient Drugs 0.000 claims 1
208000024827 Alzheimer disease Diseases 0.000 abstract description 134
230000001225 therapeutic effect Effects 0.000 abstract description 43
239000003153 chemical reaction reagent Substances 0.000 abstract description 13
208000034846 Familial Amyloid Neuropathies Diseases 0.000 abstract description 5
208000024777 Prion disease Diseases 0.000 abstract description 4
241000699670 Mus sp. Species 0.000 description 181
239000000306 component Substances 0.000 description 116
238000002649 immunization Methods 0.000 description 111
230000003053 immunization Effects 0.000 description 107
235000018102 proteins Nutrition 0.000 description 107
241001465754 Metazoa Species 0.000 description 98
210000004556 brain Anatomy 0.000 description 90
210000004027 cell Anatomy 0.000 description 86
230000002163 immunogen Effects 0.000 description 79
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 72
101710137189 Amyloid-beta A4 protein Proteins 0.000 description 69
101710151993 Amyloid-beta precursor protein Proteins 0.000 description 69
102100022704 Amyloid-beta precursor protein Human genes 0.000 description 69
235000001014 amino acid Nutrition 0.000 description 55
238000002347 injection Methods 0.000 description 55
239000007924 injection Substances 0.000 description 55
150000001413 amino acids Chemical class 0.000 description 53
239000000427 antigen Substances 0.000 description 43
108091007433 antigens Proteins 0.000 description 43
102000036639 antigens Human genes 0.000 description 43
239000003814 drug Substances 0.000 description 40
230000000694 effects Effects 0.000 description 36
230000009467 reduction Effects 0.000 description 36
210000001320 hippocampus Anatomy 0.000 description 34
210000001519 tissue Anatomy 0.000 description 34
210000001744 T-lymphocyte Anatomy 0.000 description 32
241000699666 Mus <mouse, genus> Species 0.000 description 31
238000004458 analytical method Methods 0.000 description 30
230000001054 cortical effect Effects 0.000 description 28
210000004369 blood Anatomy 0.000 description 25
239000008280 blood Substances 0.000 description 25
239000000243 solution Substances 0.000 description 25
230000035772 mutation Effects 0.000 description 24
230000002829 reductive effect Effects 0.000 description 24
230000008021 deposition Effects 0.000 description 23
238000002474 experimental method Methods 0.000 description 23
229940124597 therapeutic agent Drugs 0.000 description 23
239000000562 conjugate Substances 0.000 description 20
230000001965 increasing effect Effects 0.000 description 20
108060003951 Immunoglobulin Proteins 0.000 description 19
102000018358 immunoglobulin Human genes 0.000 description 19
108020001507 fusion proteins Proteins 0.000 description 18
102000037865 fusion proteins Human genes 0.000 description 18
230000009261 transgenic effect Effects 0.000 description 18
230000007423 decrease Effects 0.000 description 17
230000028996 humoral immune response Effects 0.000 description 17
229920001184 polypeptide Polymers 0.000 description 17
230000015572 biosynthetic process Effects 0.000 description 16
229940079593 drug Drugs 0.000 description 16
230000007170 pathology Effects 0.000 description 16
241000283973 Oryctolagus cuniculus Species 0.000 description 15
239000000872 buffer Substances 0.000 description 15
230000000971 hippocampal effect Effects 0.000 description 15
230000004044 response Effects 0.000 description 15
239000000725 suspension Substances 0.000 description 15
238000012360 testing method Methods 0.000 description 15
108020004414 DNA Proteins 0.000 description 14
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 14
206010035226 Plasma cell myeloma Diseases 0.000 description 14
238000003556 assay Methods 0.000 description 14
238000005755 formation reaction Methods 0.000 description 14
230000001939 inductive effect Effects 0.000 description 14
230000000069 prophylactic effect Effects 0.000 description 14
239000013598 vector Substances 0.000 description 14
230000002025 microglial effect Effects 0.000 description 13
238000002360 preparation method Methods 0.000 description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
239000000969 carrier Substances 0.000 description 12
210000001638 cerebellum Anatomy 0.000 description 12
150000001875 compounds Chemical class 0.000 description 12
230000002068 genetic effect Effects 0.000 description 12
238000010191 image analysis Methods 0.000 description 12
239000000463 material Substances 0.000 description 12
238000005259 measurement Methods 0.000 description 12
210000000056 organ Anatomy 0.000 description 12
108010091748 peptide A Proteins 0.000 description 12
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 11
230000007131 anti Alzheimer effect Effects 0.000 description 11
230000002490 cerebral effect Effects 0.000 description 11
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 11
210000002241 neurite Anatomy 0.000 description 11
229940031439 squalene Drugs 0.000 description 11
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 11
206010018341 Gliosis Diseases 0.000 description 10
206010057249 Phagocytosis Diseases 0.000 description 10
108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 10
238000011161 development Methods 0.000 description 10
230000018109 developmental process Effects 0.000 description 10
230000008782 phagocytosis Effects 0.000 description 10
108091033319 polynucleotide Proteins 0.000 description 10
102000040430 polynucleotide Human genes 0.000 description 10
239000002157 polynucleotide Substances 0.000 description 10
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 10
238000012216 screening Methods 0.000 description 10
238000011830 transgenic mouse model Methods 0.000 description 10
241001529936 Murinae Species 0.000 description 9
241000699660 Mus musculus Species 0.000 description 9
241001494479 Pecora Species 0.000 description 9
241000283984 Rodentia Species 0.000 description 9
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
210000005013 brain tissue Anatomy 0.000 description 9
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 9
230000003247 decreasing effect Effects 0.000 description 9
239000000839 emulsion Substances 0.000 description 9
239000002609 medium Substances 0.000 description 9
208000033808 peripheral neuropathy Diseases 0.000 description 9
235000002639 sodium chloride Nutrition 0.000 description 9
239000000126 substance Substances 0.000 description 9
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 8
210000001130 astrocyte Anatomy 0.000 description 8
210000003169 central nervous system Anatomy 0.000 description 8
230000000875 corresponding effect Effects 0.000 description 8
238000004519 manufacturing process Methods 0.000 description 8
102000039446 nucleic acids Human genes 0.000 description 8
108020004707 nucleic acids Proteins 0.000 description 8
150000007523 nucleic acids Chemical class 0.000 description 8
239000007858 starting material Substances 0.000 description 8
229960000814 tetanus toxoid Drugs 0.000 description 8
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 8
229940033663 thimerosal Drugs 0.000 description 8
241000894006 Bacteria Species 0.000 description 7
241000700198 Cavia Species 0.000 description 7
241000283073 Equus caballus Species 0.000 description 7
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 7
206010028980 Neoplasm Diseases 0.000 description 7
108091000054 Prion Proteins 0.000 description 7
208000037875 astrocytosis Diseases 0.000 description 7
230000007341 astrogliosis Effects 0.000 description 7
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 7
210000004698 lymphocyte Anatomy 0.000 description 7
239000008176 lyophilized powder Substances 0.000 description 7
238000004445 quantitative analysis Methods 0.000 description 7
239000011780 sodium chloride Substances 0.000 description 7
208000011580 syndromic disease Diseases 0.000 description 7
230000009885 systemic effect Effects 0.000 description 7
108010076119 Caseins Proteins 0.000 description 6
241000282412 Homo Species 0.000 description 6
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
241000700605 Viruses Species 0.000 description 6
150000001412 amines Chemical class 0.000 description 6
238000010171 animal model Methods 0.000 description 6
230000001413 cellular effect Effects 0.000 description 6
230000008859 change Effects 0.000 description 6
239000003085 diluting agent Substances 0.000 description 6
208000015181 infectious disease Diseases 0.000 description 6
201000000050 myeloid neoplasm Diseases 0.000 description 6
239000013642 negative control Substances 0.000 description 6
239000007764 o/w emulsion Substances 0.000 description 6
239000002245 particle Substances 0.000 description 6
230000035515 penetration Effects 0.000 description 6
230000002093 peripheral effect Effects 0.000 description 6
208000022256 primary systemic amyloidosis Diseases 0.000 description 6
230000009257 reactivity Effects 0.000 description 6
230000002441 reversible effect Effects 0.000 description 6
230000035945 sensitivity Effects 0.000 description 6
238000006467 substitution reaction Methods 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
239000003826 tablet Substances 0.000 description 6
108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
102100034452 Alternative prion protein Human genes 0.000 description 5
102000009091 Amyloidogenic Proteins Human genes 0.000 description 5
108010048112 Amyloidogenic Proteins Proteins 0.000 description 5
102000011632 Caseins Human genes 0.000 description 5
108020004705 Codon Proteins 0.000 description 5
101100289989 Drosophila melanogaster alpha-Man-Ia gene Proteins 0.000 description 5
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 description 5
108700005091 Immunoglobulin Genes Proteins 0.000 description 5
101150021286 MAS1 gene Proteins 0.000 description 5
229920004890 Triton X-100 Polymers 0.000 description 5
125000003275 alpha amino acid group Chemical group 0.000 description 5
238000001574 biopsy Methods 0.000 description 5
201000011510 cancer Diseases 0.000 description 5
239000005018 casein Substances 0.000 description 5
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 5
235000021240 caseins Nutrition 0.000 description 5
238000003776 cleavage reaction Methods 0.000 description 5
239000002158 endotoxin Substances 0.000 description 5
230000006870 function Effects 0.000 description 5
230000004927 fusion Effects 0.000 description 5
239000005556 hormone Substances 0.000 description 5
229940088597 hormone Drugs 0.000 description 5
102000046783 human APP Human genes 0.000 description 5
229940072221 immunoglobulins Drugs 0.000 description 5
238000002991 immunohistochemical analysis Methods 0.000 description 5
210000003734 kidney Anatomy 0.000 description 5
239000007788 liquid Substances 0.000 description 5
210000004185 liver Anatomy 0.000 description 5
210000000274 microglia Anatomy 0.000 description 5
238000002156 mixing Methods 0.000 description 5
210000001616 monocyte Anatomy 0.000 description 5
150000002942 palmitic acid derivatives Chemical class 0.000 description 5
230000001575 pathological effect Effects 0.000 description 5
102000013415 peroxidase activity proteins Human genes 0.000 description 5
108040007629 peroxidase activity proteins Proteins 0.000 description 5
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
229920000053 polysorbate 80 Polymers 0.000 description 5
238000011002 quantification Methods 0.000 description 5
230000007017 scission Effects 0.000 description 5
238000010186 staining Methods 0.000 description 5
230000008685 targeting Effects 0.000 description 5
238000011269 treatment regimen Methods 0.000 description 5
239000013603 viral vector Substances 0.000 description 5
108010090849 Amyloid beta-Peptides Proteins 0.000 description 4
102000013455 Amyloid beta-Peptides Human genes 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
102000004127 Cytokines Human genes 0.000 description 4
108090000695 Cytokines Proteins 0.000 description 4
201000010374 Down Syndrome Diseases 0.000 description 4
206010016202 Familial Amyloidosis Diseases 0.000 description 4
102000003886 Glycoproteins Human genes 0.000 description 4
108090000288 Glycoproteins Proteins 0.000 description 4
206010019889 Hereditary neuropathic amyloidosis Diseases 0.000 description 4
229920001213 Polysorbate 20 Polymers 0.000 description 4
240000004808 Saccharomyces cerevisiae Species 0.000 description 4
101710190759 Serum amyloid A protein Proteins 0.000 description 4
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
230000005867 T cell response Effects 0.000 description 4
108700019146 Transgenes Proteins 0.000 description 4
239000013504 Triton X-100 Substances 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
230000032683 aging Effects 0.000 description 4
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 4
229940024545 aluminum hydroxide Drugs 0.000 description 4
238000013459 approach Methods 0.000 description 4
230000001580 bacterial effect Effects 0.000 description 4
150000001720 carbohydrates Chemical class 0.000 description 4
210000003710 cerebral cortex Anatomy 0.000 description 4
210000001175 cerebrospinal fluid Anatomy 0.000 description 4
230000001684 chronic effect Effects 0.000 description 4
238000004140 cleaning Methods 0.000 description 4
239000008367 deionised water Substances 0.000 description 4
229910021641 deionized water Inorganic materials 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
238000009826 distribution Methods 0.000 description 4
239000003623 enhancer Substances 0.000 description 4
239000013604 expression vector Substances 0.000 description 4
239000012530 fluid Substances 0.000 description 4
238000009472 formulation Methods 0.000 description 4
238000001631 haemodialysis Methods 0.000 description 4
230000000322 hemodialysis Effects 0.000 description 4
210000004408 hybridoma Anatomy 0.000 description 4
230000001900 immune effect Effects 0.000 description 4
230000002055 immunohistochemical effect Effects 0.000 description 4
239000003022 immunostimulating agent Substances 0.000 description 4
239000002502 liposome Substances 0.000 description 4
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 4
210000002540 macrophage Anatomy 0.000 description 4
238000012544 monitoring process Methods 0.000 description 4
230000001537 neural effect Effects 0.000 description 4
230000002981 neuropathic effect Effects 0.000 description 4
230000007171 neuropathology Effects 0.000 description 4
239000003921 oil Substances 0.000 description 4
235000019198 oils Nutrition 0.000 description 4
239000000863 peptide conjugate Substances 0.000 description 4
239000012071 phase Substances 0.000 description 4
210000002381 plasma Anatomy 0.000 description 4
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
230000002062 proliferating effect Effects 0.000 description 4
238000003259 recombinant expression Methods 0.000 description 4
238000011160 research Methods 0.000 description 4
230000003248 secreting effect Effects 0.000 description 4
239000001488 sodium phosphate Substances 0.000 description 4
229910000162 sodium phosphate Inorganic materials 0.000 description 4
239000002904 solvent Substances 0.000 description 4
238000001228 spectrum Methods 0.000 description 4
210000000952 spleen Anatomy 0.000 description 4
238000010561 standard procedure Methods 0.000 description 4
238000003756 stirring Methods 0.000 description 4
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 4
238000012546 transfer Methods 0.000 description 4
201000007905 transthyretin amyloidosis Diseases 0.000 description 4
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 4
201000008827 tuberculosis Diseases 0.000 description 4
238000001262 western blot Methods 0.000 description 4
MFRCZYUUKMFJQJ-UHFFFAOYSA-N 1,4-dioxane-2,5-dione;1,3-dioxan-2-one Chemical compound O=C1OCCCO1.O=C1COC(=O)CO1 MFRCZYUUKMFJQJ-UHFFFAOYSA-N 0.000 description 3
208000000044 Amnesia Diseases 0.000 description 3
206010002023 Amyloidoses Diseases 0.000 description 3
108010083590 Apoproteins Proteins 0.000 description 3
102000006410 Apoproteins Human genes 0.000 description 3
206010061666 Autonomic neuropathy Diseases 0.000 description 3
102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 description 3
241000283707 Capra Species 0.000 description 3
208000031229 Cardiomyopathies Diseases 0.000 description 3
208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 3
208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 3
208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 3
244000019459 Cynara cardunculus Species 0.000 description 3
235000019106 Cynara scolymus Nutrition 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
241000238631 Hexapoda Species 0.000 description 3
102000013463 Immunoglobulin Light Chains Human genes 0.000 description 3
108010065825 Immunoglobulin Light Chains Proteins 0.000 description 3
208000026350 Inborn Genetic disease Diseases 0.000 description 3
206010024229 Leprosy Diseases 0.000 description 3
208000026139 Memory disease Diseases 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
108091028043 Nucleic acid sequence Proteins 0.000 description 3
229930040373 Paraformaldehyde Natural products 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
108010029485 Protein Isoforms Proteins 0.000 description 3
102000001708 Protein Isoforms Human genes 0.000 description 3
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
230000009471 action Effects 0.000 description 3
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 3
125000000539 amino acid group Chemical group 0.000 description 3
235000016520 artichoke thistle Nutrition 0.000 description 3
230000001746 atrial effect Effects 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
230000008499 blood brain barrier function Effects 0.000 description 3
210000001218 blood-brain barrier Anatomy 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
239000004202 carbamide Substances 0.000 description 3
210000002421 cell wall Anatomy 0.000 description 3
208000037976 chronic inflammation Diseases 0.000 description 3
238000010276 construction Methods 0.000 description 3
229920001577 copolymer Polymers 0.000 description 3
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
235000018417 cysteine Nutrition 0.000 description 3
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
230000003111 delayed effect Effects 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
210000001947 dentate gyrus Anatomy 0.000 description 3
238000003745 diagnosis Methods 0.000 description 3
238000000502 dialysis Methods 0.000 description 3
231100000673 dose–response relationship Toxicity 0.000 description 3
239000012636 effector Substances 0.000 description 3
230000002124 endocrine Effects 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
239000000284 extract Substances 0.000 description 3
238000000605 extraction Methods 0.000 description 3
239000000945 filler Substances 0.000 description 3
210000005153 frontal cortex Anatomy 0.000 description 3
208000016361 genetic disease Diseases 0.000 description 3
239000011521 glass Substances 0.000 description 3
230000007387 gliosis Effects 0.000 description 3
210000005003 heart tissue Anatomy 0.000 description 3
208000017105 hereditary amyloidosis Diseases 0.000 description 3
230000005847 immunogenicity Effects 0.000 description 3
230000003308 immunostimulating effect Effects 0.000 description 3
238000011534 incubation Methods 0.000 description 3
230000006698 induction Effects 0.000 description 3
238000002372 labelling Methods 0.000 description 3
230000003902 lesion Effects 0.000 description 3
210000000265 leukocyte Anatomy 0.000 description 3
210000004962 mammalian cell Anatomy 0.000 description 3
230000006984 memory degeneration Effects 0.000 description 3
208000023060 memory loss Diseases 0.000 description 3
230000000813 microbial effect Effects 0.000 description 3
239000003226 mitogen Substances 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
239000002052 molecular layer Substances 0.000 description 3
229940035032 monophosphoryl lipid a Drugs 0.000 description 3
230000007823 neuropathy Effects 0.000 description 3
201000001119 neuropathy Diseases 0.000 description 3
210000004940 nucleus Anatomy 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
229920002866 paraformaldehyde Polymers 0.000 description 3
108010049224 perlecan Proteins 0.000 description 3
238000002823 phage display Methods 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
239000000902 placebo Substances 0.000 description 3
229940068196 placebo Drugs 0.000 description 3
229920000747 poly(lactic acid) Polymers 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
239000013641 positive control Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
238000012545 processing Methods 0.000 description 3
230000000750 progressive effect Effects 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
230000006337 proteolytic cleavage Effects 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
206010039073 rheumatoid arthritis Diseases 0.000 description 3
150000007949 saponins Chemical class 0.000 description 3
230000009870 specific binding Effects 0.000 description 3
210000004989 spleen cell Anatomy 0.000 description 3
210000004988 splenocyte Anatomy 0.000 description 3
239000000829 suppository Substances 0.000 description 3
238000004448 titration Methods 0.000 description 3
238000001890 transfection Methods 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
108700028369 Alleles Proteins 0.000 description 2
241000710929 Alphavirus Species 0.000 description 2
102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 2
206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
208000036487 Arthropathies Diseases 0.000 description 2
206010003445 Ascites Diseases 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
206010004146 Basal cell carcinoma Diseases 0.000 description 2
208000027496 Behcet disease Diseases 0.000 description 2
208000009137 Behcet syndrome Diseases 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
102000055006 Calcitonin Human genes 0.000 description 2
108060001064 Calcitonin Proteins 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
208000035473 Communicable disease Diseases 0.000 description 2
108010047041 Complementarity Determining Regions Proteins 0.000 description 2
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
241000700626 Cowpox virus Species 0.000 description 2
208000011231 Crohn disease Diseases 0.000 description 2
206010012289 Dementia Diseases 0.000 description 2
229920000045 Dermatan sulfate Polymers 0.000 description 2
238000009007 Diagnostic Kit Methods 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
102000053171 Glial Fibrillary Acidic Human genes 0.000 description 2
101710193519 Glial fibrillary acidic protein Proteins 0.000 description 2
208000005232 Glossitis Diseases 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical class NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
244000068988 Glycine max Species 0.000 description 2
235000010469 Glycine max Nutrition 0.000 description 2
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
102000015779 HDL Lipoproteins Human genes 0.000 description 2
108010010234 HDL Lipoproteins Proteins 0.000 description 2
229920002971 Heparan sulfate Polymers 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
208000017604 Hodgkin disease Diseases 0.000 description 2
208000021519 Hodgkin lymphoma Diseases 0.000 description 2
208000010747 Hodgkins lymphoma Diseases 0.000 description 2
208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 description 2
208000012659 Joint disease Diseases 0.000 description 2
208000003456 Juvenile Arthritis Diseases 0.000 description 2
206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
208000008839 Kidney Neoplasms Diseases 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
208000034578 Multiple myelomas Diseases 0.000 description 2
SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
206010031256 Osteomyelitis chronic Diseases 0.000 description 2
240000002834 Paulownia tomentosa Species 0.000 description 2
235000010678 Paulownia tomentosa Nutrition 0.000 description 2
235000019483 Peanut oil Nutrition 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
102000015731 Peptide Hormones Human genes 0.000 description 2
108010038988 Peptide Hormones Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
229920000954 Polyglycolide Polymers 0.000 description 2
108010039918 Polylysine Proteins 0.000 description 2
208000004210 Pressure Ulcer Diseases 0.000 description 2
102000029797 Prion Human genes 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
208000036824 Psoriatic arthropathy Diseases 0.000 description 2
206010037601 Pyelonephritis chronic Diseases 0.000 description 2
208000001647 Renal Insufficiency Diseases 0.000 description 2
206010038389 Renal cancer Diseases 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
108010090804 Streptavidin Proteins 0.000 description 2
208000024770 Thyroid neoplasm Diseases 0.000 description 2
239000007997 Tricine buffer Substances 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
235000009108 Urtica dioica Nutrition 0.000 description 2
241000710959 Venezuelan equine encephalitis virus Species 0.000 description 2
241000251539 Vertebrata <Metazoa> Species 0.000 description 2
241000711975 Vesicular stomatitis virus Species 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
239000002253 acid Substances 0.000 description 2
210000001642 activated microglia Anatomy 0.000 description 2
230000004913 activation Effects 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
230000002411 adverse Effects 0.000 description 2
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
235000003704 aspartic acid Nutrition 0.000 description 2
230000002238 attenuated effect Effects 0.000 description 2
230000001363 autoimmune Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
230000001588 bifunctional effect Effects 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
230000037396 body weight Effects 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
201000009267 bronchiectasis Diseases 0.000 description 2
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
229960004015 calcitonin Drugs 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000011575 calcium Substances 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
229940094517 chondroitin 4-sulfate Drugs 0.000 description 2
KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 2
208000037893 chronic inflammatory disorder Diseases 0.000 description 2
201000006368 chronic pyelonephritis Diseases 0.000 description 2
238000010367 cloning Methods 0.000 description 2
208000029742 colonic neoplasm Diseases 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 2
230000021615 conjugation Effects 0.000 description 2
229910052802 copper Inorganic materials 0.000 description 2
239000010949 copper Substances 0.000 description 2
230000009260 cross reactivity Effects 0.000 description 2
NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 2
230000021953 cytokinesis Effects 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
230000005786 degenerative changes Effects 0.000 description 2
229940051593 dermatan sulfate Drugs 0.000 description 2
AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 2
238000001514 detection method Methods 0.000 description 2
239000003599 detergent Substances 0.000 description 2
229960000633 dextran sulfate Drugs 0.000 description 2
238000002405 diagnostic procedure Methods 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
210000005110 dorsal hippocampus Anatomy 0.000 description 2
230000008030 elimination Effects 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
201000006061 fatal familial insomnia Diseases 0.000 description 2
239000000834 fixative Substances 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
210000005046 glial fibrillary acidic protein Anatomy 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
108060003552 hemocyanin Proteins 0.000 description 2
230000001744 histochemical effect Effects 0.000 description 2
239000012456 homogeneous solution Substances 0.000 description 2
210000004754 hybrid cell Anatomy 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
230000003100 immobilizing effect Effects 0.000 description 2
238000003364 immunohistochemistry Methods 0.000 description 2
239000007943 implant Substances 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
238000007917 intracranial administration Methods 0.000 description 2
238000010255 intramuscular injection Methods 0.000 description 2
239000007927 intramuscular injection Substances 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
230000001788 irregular Effects 0.000 description 2
201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 2
201000010982 kidney cancer Diseases 0.000 description 2
208000017169 kidney disease Diseases 0.000 description 2
201000006370 kidney failure Diseases 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000004816 latex Substances 0.000 description 2
229920000126 latex Polymers 0.000 description 2
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
230000031700 light absorption Effects 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
230000001589 lymphoproliferative effect Effects 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000036210 malignancy Effects 0.000 description 2
239000003550 marker Substances 0.000 description 2
239000000693 micelle Substances 0.000 description 2
230000007388 microgliosis Effects 0.000 description 2
210000002569 neuron Anatomy 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
230000000242 pagocytic effect Effects 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
230000008506 pathogenesis Effects 0.000 description 2
239000000312 peanut oil Substances 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
229940043138 pentosan polysulfate Drugs 0.000 description 2
238000010647 peptide synthesis reaction Methods 0.000 description 2
210000000578 peripheral nerve Anatomy 0.000 description 2
210000001539 phagocyte Anatomy 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
KAICRBBQCRKMPO-UHFFFAOYSA-N phosphoric acid;pyridine-3,4-diamine Chemical compound OP(O)(O)=O.NC1=CC=NC=C1N KAICRBBQCRKMPO-UHFFFAOYSA-N 0.000 description 2
230000007505 plaque formation Effects 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
210000004180 plasmocyte Anatomy 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920000656 polylysine Polymers 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
230000009696 proliferative response Effects 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
239000001397 quillaja saponaria molina bark Substances 0.000 description 2
230000007342 reactive astrogliosis Effects 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
229930182490 saponin Natural products 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
230000002000 scavenging effect Effects 0.000 description 2
230000028327 secretion Effects 0.000 description 2
241000894007 species Species 0.000 description 2
229960005322 streptomycin Drugs 0.000 description 2
239000000758 substrate Substances 0.000 description 2
229960002317 succinimide Drugs 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000002123 temporal effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
238000011285 therapeutic regimen Methods 0.000 description 2
150000007970 thio esters Chemical class 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
201000002510 thyroid cancer Diseases 0.000 description 2
231100000027 toxicology Toxicity 0.000 description 2
231100000041 toxicology testing Toxicity 0.000 description 2
230000001131 transforming effect Effects 0.000 description 2
238000011820 transgenic animal model Methods 0.000 description 2
230000032258 transport Effects 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
102000003390 tumor necrosis factor Human genes 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
230000002861 ventricular Effects 0.000 description 2
239000011534 wash buffer Substances 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
UDPGUMQDCGORJQ-UHFFFAOYSA-N (2-chloroethyl)phosphonic acid Chemical compound OP(O)(=O)CCCl UDPGUMQDCGORJQ-UHFFFAOYSA-N 0.000 description 1
HONKEGXLWUDTCF-YFKPBYRVSA-N (2s)-2-amino-2-methyl-4-phosphonobutanoic acid Chemical compound OC(=O)[C@](N)(C)CCP(O)(O)=O HONKEGXLWUDTCF-YFKPBYRVSA-N 0.000 description 1
BCHIXGBGRHLSBE-UHFFFAOYSA-N (4-methyl-2-oxochromen-7-yl) dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C=CC2=C1OC(=O)C=C2C BCHIXGBGRHLSBE-UHFFFAOYSA-N 0.000 description 1
230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 1
NGEZPLCPKXKLQQ-VOTSOKGWSA-N (e)-4-(3-methoxyphenyl)but-3-en-2-one Chemical compound COC1=CC=CC(\C=C\C(C)=O)=C1 NGEZPLCPKXKLQQ-VOTSOKGWSA-N 0.000 description 1
LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
QDSAUUOUBPKTKQ-UHFFFAOYSA-N 2-(2,4-dihydroxyphenyl)-4,5,7-trihydroxy-4H-chromen-3-one Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(=O)C1C1=CC=C(O)C=C1O QDSAUUOUBPKTKQ-UHFFFAOYSA-N 0.000 description 1
SEXCXAIQIMWSBF-UHFFFAOYSA-N 2-methyl-2,8-diazaspiro[4.5]decane Chemical compound C1N(C)CCC21CCNCC2 SEXCXAIQIMWSBF-UHFFFAOYSA-N 0.000 description 1
QPILHXCDZYWYLQ-UHFFFAOYSA-N 2-nonyl-1,3-dioxolane Chemical compound CCCCCCCCCC1OCCO1 QPILHXCDZYWYLQ-UHFFFAOYSA-N 0.000 description 1
HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
229940117976 5-hydroxylysine Drugs 0.000 description 1
208000023769 AA amyloidosis Diseases 0.000 description 1
244000298715 Actinidia chinensis Species 0.000 description 1
235000009434 Actinidia chinensis Nutrition 0.000 description 1
235000009436 Actinidia deliciosa Nutrition 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
102000014303 Amyloid beta-Protein Precursor Human genes 0.000 description 1
108010079054 Amyloid beta-Protein Precursor Proteins 0.000 description 1
108010032595 Antibody Binding Sites Proteins 0.000 description 1
102000005666 Apolipoprotein A-I Human genes 0.000 description 1
108010059886 Apolipoprotein A-I Proteins 0.000 description 1
108010060159 Apolipoprotein E4 Proteins 0.000 description 1
108010071619 Apolipoproteins Proteins 0.000 description 1
102000007592 Apolipoproteins Human genes 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
241001167018 Aroa Species 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
231100000699 Bacterial toxin Toxicity 0.000 description 1
208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
102100023006 Basic leucine zipper transcriptional factor ATF-like 2 Human genes 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
241000701822 Bovine papillomavirus Species 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
108090000565 Capsid Proteins Proteins 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
102100023321 Ceruloplasmin Human genes 0.000 description 1
101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
206010008631 Cholera Diseases 0.000 description 1
102000009016 Cholera Toxin Human genes 0.000 description 1
108010049048 Cholera Toxin Proteins 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
208000028698 Cognitive impairment Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
244000205754 Colocasia esculenta Species 0.000 description 1
235000006481 Colocasia esculenta Nutrition 0.000 description 1
208000019736 Cranial nerve disease Diseases 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
208000031124 Dementia Alzheimer type Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
102000002322 Egg Proteins Human genes 0.000 description 1
108010000912 Egg Proteins Proteins 0.000 description 1
101100491986 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) aromA gene Proteins 0.000 description 1
241000305071 Enterobacterales Species 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
206010015548 Euthanasia Diseases 0.000 description 1
206010016207 Familial Mediterranean fever Diseases 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102400000524 Fibrinogen alpha chain Human genes 0.000 description 1
101710137044 Fibrinogen alpha chain Proteins 0.000 description 1
241000700662 Fowlpox virus Species 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010053240 Glycogen storage disease type VI Diseases 0.000 description 1
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
208000010496 Heart Arrest Diseases 0.000 description 1
101710154606 Hemagglutinin Proteins 0.000 description 1
206010019842 Hepatomegaly Diseases 0.000 description 1
208000003923 Hereditary Corneal Dystrophies Diseases 0.000 description 1
208000028782 Hereditary disease Diseases 0.000 description 1
229920000209 Hexadimethrine bromide Polymers 0.000 description 1
101100268553 Homo sapiens APP gene Proteins 0.000 description 1
101000903615 Homo sapiens Basic leucine zipper transcriptional factor ATF-like 2 Proteins 0.000 description 1
101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 1
101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
101000616438 Homo sapiens Microtubule-associated protein 4 Proteins 0.000 description 1
101000851593 Homo sapiens Separin Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical class O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
102100022338 Integrin alpha-M Human genes 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
102000008192 Lactoglobulins Human genes 0.000 description 1
108010060630 Lactoglobulins Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
102100039564 Leukosialin Human genes 0.000 description 1
108010005832 Leukosialin Proteins 0.000 description 1
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
102000043129 MHC class I family Human genes 0.000 description 1
108091054437 MHC class I family Proteins 0.000 description 1
108010030317 Macrophage-1 Antigen Proteins 0.000 description 1
101000962498 Macropis fulvipes Macropin Proteins 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
244000070406 Malus silvestris Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
101150076359 Mhc gene Proteins 0.000 description 1
102100021794 Microtubule-associated protein 4 Human genes 0.000 description 1
206010060880 Monoclonal gammopathy Diseases 0.000 description 1
JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
206010029240 Neuritis Diseases 0.000 description 1
229910021586 Nickel(II) chloride Inorganic materials 0.000 description 1
241000289371 Ornithorhynchus anatinus Species 0.000 description 1
206010031127 Orthostatic hypotension Diseases 0.000 description 1
206010031252 Osteomyelitis Diseases 0.000 description 1
101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
241001631646 Papillomaviridae Species 0.000 description 1
208000002774 Paraproteinemias Diseases 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
108010067902 Peptide Library Proteins 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
108010020346 Polyglutamic Acid Proteins 0.000 description 1
108010076039 Polyproteins Proteins 0.000 description 1
102000007584 Prealbumin Human genes 0.000 description 1
241000288906 Primates Species 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
239000004365 Protease Substances 0.000 description 1
101710176177 Protein A56 Proteins 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
208000035977 Rare disease Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
206010062237 Renal impairment Diseases 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
241000956335 Rysops Species 0.000 description 1
WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
206010039966 Senile dementia Diseases 0.000 description 1
102100036750 Separin Human genes 0.000 description 1
241000607768 Shigella Species 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
108010055044 Tetanus Toxin Proteins 0.000 description 1
102000009843 Thyroglobulin Human genes 0.000 description 1
108010034949 Thyroglobulin Proteins 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
206010044688 Trisomy 21 Diseases 0.000 description 1
208000008385 Urogenital Neoplasms Diseases 0.000 description 1
244000274883 Urtica dioica Species 0.000 description 1
241000218215 Urticaceae Species 0.000 description 1
241000021394 Veia Species 0.000 description 1
241000405119 Virga Species 0.000 description 1
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
102000007544 Whey Proteins Human genes 0.000 description 1
108010046377 Whey Proteins Proteins 0.000 description 1
208000027207 Whipple disease Diseases 0.000 description 1
208000016463 Wild type ABeta2M amyloidosis Diseases 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
102100023870 YLP motif-containing protein 1 Human genes 0.000 description 1
LXEKPEMOWBOYRF-UHFFFAOYSA-N [2-[(1-azaniumyl-1-imino-2-methylpropan-2-yl)diazenyl]-2-methylpropanimidoyl]azanium;dichloride Chemical compound Cl.Cl.NC(=N)C(C)(C)N=NC(C)(C)C(N)=N LXEKPEMOWBOYRF-UHFFFAOYSA-N 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
230000001919 adrenal effect Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
229940024546 aluminum hydroxide gel Drugs 0.000 description 1
SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
PLOPBXQQPZYQFA-AXPWDRQUSA-N amlintide Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)CSSC1)[C@@H](C)O)C(C)C)C1=CC=CC=C1 PLOPBXQQPZYQFA-AXPWDRQUSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
230000006933 amyloid-beta aggregation Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000002788 anti-peptide Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
238000009175 antibody therapy Methods 0.000 description 1
210000000628 antibody-producing cell Anatomy 0.000 description 1
230000030741 antigen processing and presentation Effects 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
235000021016 apples Nutrition 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
101150037081 aroA gene Proteins 0.000 description 1
150000001491 aromatic compounds Chemical class 0.000 description 1
230000005784 autoimmunity Effects 0.000 description 1
210000003050 axon Anatomy 0.000 description 1
230000003376 axonal effect Effects 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
239000000688 bacterial toxin Substances 0.000 description 1
239000003855 balanced salt solution Substances 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
210000002469 basement membrane Anatomy 0.000 description 1
210000003651 basophil Anatomy 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
150000001557 benzodiazepines Chemical class 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
108091007737 beta-secretases Proteins 0.000 description 1
239000003150 biochemical marker Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
230000002051 biphasic effect Effects 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
239000012503 blood component Substances 0.000 description 1
230000036765 blood level Effects 0.000 description 1
229910021538 borax Inorganic materials 0.000 description 1
KDPAWGWELVVRCH-UHFFFAOYSA-N bromoacetic acid Chemical compound OC(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-N 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
244000309464 bull Species 0.000 description 1
229960003150 bupivacaine Drugs 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
238000011088 calibration curve Methods 0.000 description 1
239000002775 capsule Substances 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
208000003295 carpal tunnel syndrome Diseases 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
235000019994 cava Nutrition 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
230000007541 cellular toxicity Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000010382 chemical cross-linking Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
210000002987 choroid plexus Anatomy 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
208000035850 clinical syndrome Diseases 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
239000013256 coordination polymer Substances 0.000 description 1
206010011005 corneal dystrophy Diseases 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
238000004690 coupled electron pair approximation Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
208000014826 cranial nerve neuropathy Diseases 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
239000002577 cryoprotective agent Substances 0.000 description 1
229960003067 cystine Drugs 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
230000003436 cytoskeletal effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
238000013461 design Methods 0.000 description 1
229950006137 dexfosfoserine Drugs 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
229910003460 diamond Inorganic materials 0.000 description 1
239000010432 diamond Substances 0.000 description 1
238000011496 digital image analysis Methods 0.000 description 1
KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
206010013023 diphtheria Diseases 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
238000002224 dissection Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Chemical class OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
235000014103 egg white Nutrition 0.000 description 1
210000000969 egg white Anatomy 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000004945 emulsification Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
229960003699 evans blue Drugs 0.000 description 1
230000005284 excitation Effects 0.000 description 1
238000013401 experimental design Methods 0.000 description 1
238000013213 extrapolation Methods 0.000 description 1
239000004744 fabric Substances 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
239000000835 fiber Substances 0.000 description 1
230000003619 fibrillary effect Effects 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000013020 final formulation Substances 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
108091007739 gamma-secretases Proteins 0.000 description 1
102000038383 gamma-secretases Human genes 0.000 description 1
150000002270 gangliosides Chemical class 0.000 description 1
239000007789 gas Substances 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
230000002518 glial effect Effects 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
235000013905 glycine and its sodium salt Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
230000002414 glycolytic effect Effects 0.000 description 1
210000002149 gonad Anatomy 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
229940029575 guanosine Drugs 0.000 description 1
210000004326 gyrus cinguli Anatomy 0.000 description 1
201000009277 hairy cell leukemia Diseases 0.000 description 1
210000003128 head Anatomy 0.000 description 1
239000001307 helium Substances 0.000 description 1
229910052734 helium Inorganic materials 0.000 description 1
SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
239000000185 hemagglutinin Substances 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
150000002391 heterocyclic compounds Chemical class 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
239000008241 heterogeneous mixture Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
210000004124 hock Anatomy 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
239000003906 humectant Substances 0.000 description 1
230000008348 humoral response Effects 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000036039 immunity Effects 0.000 description 1
229960001438 immunostimulant agent Drugs 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
230000010365 information processing Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
230000015788 innate immune response Effects 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
238000011998 interferon-gamma release assay Methods 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
230000007794 irritation Effects 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
229960002725 isoflurane Drugs 0.000 description 1
AEFLONBTGZFSGQ-UHFFFAOYSA-N isoglutamine Chemical compound NC(=O)C(N)CCC(O)=O AEFLONBTGZFSGQ-UHFFFAOYSA-N 0.000 description 1
238000005304 joining Methods 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000004310 lactic acid Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
108010052968 leupeptin Proteins 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
210000003712 lysosome Anatomy 0.000 description 1
230000001868 lysosomic effect Effects 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000008774 maternal effect Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
239000002923 metal particle Substances 0.000 description 1
210000001872 metatarsal bone Anatomy 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
150000002741 methionine derivatives Chemical class 0.000 description 1
YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
239000000178 monomer Substances 0.000 description 1
230000004660 morphological change Effects 0.000 description 1
239000012120 mounting media Substances 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
229940126619 mouse monoclonal antibody Drugs 0.000 description 1
125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
230000001452 natriuretic effect Effects 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
230000000626 neurodegenerative effect Effects 0.000 description 1
230000003961 neuronal insult Effects 0.000 description 1
230000007121 neuropathological change Effects 0.000 description 1
210000004179 neuropil Anatomy 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
238000012758 nuclear staining Methods 0.000 description 1
230000006911 nucleation Effects 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
210000002475 olfactory pathway Anatomy 0.000 description 1
210000000287 oocyte Anatomy 0.000 description 1
230000010494 opalescence Effects 0.000 description 1
210000004681 ovum Anatomy 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
239000006174 pH buffer Substances 0.000 description 1
239000005022 packaging material Substances 0.000 description 1
210000004738 parenchymal cell Anatomy 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
210000001871 perforant pathway Anatomy 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
206010034674 peritonitis Diseases 0.000 description 1
230000002688 persistence Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
239000003209 petroleum derivative Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229940067631 phospholipid Drugs 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000000049 pigment Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
238000001907 polarising light microscopy Methods 0.000 description 1
229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
229920002643 polyglutamic acid Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
231100000857 poor renal function Toxicity 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000002516 postimmunization Effects 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
244000144977 poultry Species 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002028 premature Effects 0.000 description 1
230000003518 presynaptic effect Effects 0.000 description 1
210000000063 presynaptic terminal Anatomy 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
201000001474 proteinuria Diseases 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
230000036647 reaction Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
239000001044 red dye Substances 0.000 description 1
208000012263 renal involvement Diseases 0.000 description 1
230000010076 replication Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
238000012502 risk assessment Methods 0.000 description 1
239000012898 sample dilution Substances 0.000 description 1
238000005070 sampling Methods 0.000 description 1
238000007790 scraping Methods 0.000 description 1
210000001625 seminal vesicle Anatomy 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
230000035939 shock Effects 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
235000010339 sodium tetraborate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000003860 storage Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
210000000225 synapse Anatomy 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
239000003760 tallow Substances 0.000 description 1
229940118376 tetanus toxin Drugs 0.000 description 1
238000009210 therapy by ultrasound Methods 0.000 description 1
230000008719 thickening Effects 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
229960002175 thyroglobulin Drugs 0.000 description 1
239000005495 thyroid hormone Substances 0.000 description 1
229940036555 thyroid hormone Drugs 0.000 description 1
101150022210 tim gene Proteins 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
108091005703 transmembrane proteins Proteins 0.000 description 1
102000035160 transmembrane proteins Human genes 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000003656 tris buffered saline Substances 0.000 description 1
BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
230000008728 vascular permeability Effects 0.000 description 1
UGCDBQWJXSAYIL-UHFFFAOYSA-N vat blue 6 Chemical compound O=C1C2=CC=CC=C2C(=O)C(C=C2Cl)=C1C1=C2NC2=C(C(=O)C=3C(=CC=CC=3)C3=O)C3=CC(Cl)=C2N1 UGCDBQWJXSAYIL-UHFFFAOYSA-N 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
201000010653 vesiculitis Diseases 0.000 description 1
210000002845 virion Anatomy 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
235000019155 vitamin A Nutrition 0.000 description 1
239000011719 vitamin A Substances 0.000 description 1
229940045997 vitamin a Drugs 0.000 description 1
238000003260 vortexing Methods 0.000 description 1
235000021119 whey protein Nutrition 0.000 description 1
208000027121 wild type ATTR amyloidosis Diseases 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Molecular Biology (AREA)
Neurology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Obesity (AREA)
Food Science & Technology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Rheumatology (AREA)
Analytical Chemistry (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Physics & Mathematics (AREA)
Mycology (AREA)
Cell Biology (AREA)

UA2001118223A 1999-06-01 2000-01-06 Prevention and treatment of amyloid disease UA81216C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US13701099P	1999-06-01	1999-06-01
PCT/US2000/015239 WO2000072876A2 (fr)	1999-06-01	2000-06-01	Prevention et traitement de maladies amyloidogenes

Publications (1)

Publication Number	Publication Date
UA81216C2 true UA81216C2 (en)	2007-12-25

Family

ID=22475417

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2001118223A UA81216C2 (en)	1999-06-01	2000-01-06	Prevention and treatment of amyloid disease

Country Status (31)

Country	Link
US (8)	US7977316B2 (fr)
EP (2)	EP1185296B1 (fr)
KR (3)	KR101142772B1 (fr)
CN (2)	CN101091795A (fr)
AT (1)	ATE495755T1 (fr)
AU (1)	AU5316300A (fr)
BG (1)	BG65756B1 (fr)
BR (1)	BR0011103A (fr)
CA (1)	CA2375104C (fr)
CY (1)	CY1111639T1 (fr)
CZ (1)	CZ302971B6 (fr)
DE (1)	DE60045550D1 (fr)
EA (1)	EA200101250A1 (fr)
EE (1)	EE05492B1 (fr)
ES (2)	ES2445799T3 (fr)
HK (1)	HK1045117B (fr)
HR (1)	HRP20010893A2 (fr)
HU (1)	HU229986B1 (fr)
IL (3)	IL146563A0 (fr)
IS (1)	IS2925B (fr)
MX (1)	MXPA01012293A (fr)
NO (1)	NO20015758L (fr)
NZ (2)	NZ556622A (fr)
PL (1)	PL202217B1 (fr)
PT (1)	PT1185296E (fr)
SG (2)	SG147275A1 (fr)
SK (1)	SK288207B6 (fr)
TR (1)	TR200103469T2 (fr)
UA (1)	UA81216C2 (fr)
WO (1)	WO2000072876A2 (fr)
ZA (1)	ZA200109662B (fr)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9706957D0 (en)	1997-04-05	1997-05-21	Smithkline Beecham Plc	Formulation
US8173127B2 (en) *	1997-04-09	2012-05-08	Intellect Neurosciences, Inc.	Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US6905686B1 (en)	1997-12-02	2005-06-14	Neuralab Limited	Active immunization for treatment of alzheimer's disease
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
US6787523B1 (en)	1997-12-02	2004-09-07	Neuralab Limited	Prevention and treatment of amyloidogenic disease
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6913745B1 (en)	1997-12-02	2005-07-05	Neuralab Limited	Passive immunization of Alzheimer's disease
US6761888B1 (en)	2000-05-26	2004-07-13	Neuralab Limited	Passive immunization treatment of Alzheimer's disease
US7790856B2 (en)	1998-04-07	2010-09-07	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en)	2000-05-26	2009-09-15	Elan Pharma International Limited	Treatment of amyloidogenic disease
US7179892B2 (en)	2000-12-06	2007-02-20	Neuralab Limited	Humanized antibodies that recognize beta amyloid peptide
US20030147882A1 (en)	1998-05-21	2003-08-07	Alan Solomon	Methods for amyloid removal using anti-amyloid antibodies
GB9820525D0 (en)	1998-09-21	1998-11-11	Allergy Therapeutics Ltd	Formulation
EP2204186B1 (fr)	1999-02-17	2016-04-06	CSL Limited	Complexes immunogènes et méthodes y relatives
US6787637B1 (en)	1999-05-28	2004-09-07	Neuralab Limited	N-Terminal amyloid-β antibodies
UA81216C2 (en)	1999-06-01	2007-12-25		Prevention and treatment of amyloid disease
CN1414976A (zh)	1999-12-08	2003-04-30	明德塞特生物制药(美国)公司	作为免疫原的嵌合肽及其抗体,以及利用嵌合肽或抗体进行免疫的方法
GB0000891D0 (en)	2000-01-14	2000-03-08	Allergy Therapeutics Ltd	Formulation
KR100767146B1 (ko)	2000-02-24	2007-10-15	워싱톤 유니버시티	Ａβ 펩티드를 격리시키는 인간화 항체
CA2404237C (fr)	2000-04-05	2010-01-26	University Of Tennessee Research Corporation	Techniques d'etude, de diagnostic et de traitement d'amylose
WO2002003911A2 (fr)	2000-07-07	2002-01-17	Lars Lannfelt	Prevention et traitement de la maladie d'alzheimer
AU2007200047B2 (en) *	2000-07-07	2009-11-26	Bioarctic Neuroscience Ab	Prevention and treatment of Alzheimer's disease
PE20020574A1 (es)	2000-12-06	2002-07-02	Wyeth Corp	Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en)	2000-12-06	2010-04-20	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize β-amyloid peptide
ATE420114T1 (de)	2001-04-30	2009-01-15	Lilly Co Eli	Humanisierte antikörper die das beta-amyloid peptid erkennen& x9;
WO2002088307A2 (fr)	2001-04-30	2002-11-07	Eli Lilly And Company	Anticorps humanises
US6906169B2 (en) *	2001-05-25	2005-06-14	United Biomedical, Inc.	Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
DK1944040T3 (da)	2001-08-17	2012-10-29	Univ Washington	Analysefremgangsmåde for Alzheimers sygdom
US20050227941A1 (en) *	2001-12-17	2005-10-13	Karen Duff	Sequestration of ass in the periphery in the absence of immunomodulating agent as a therapeutic approach for the treatment or prevention of beta-amyloid related diseases
US20060210555A1 (en) *	2001-12-21	2006-09-21	Antigenics, Inc.	Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
CA2493119A1 (fr) *	2002-07-17	2004-01-22	Mindset Biopharmaceuticals Usa Inc.	Peptides et procedes de criblage de vaccins a base de peptides immunogenes contre la maladie d'alzheimer
US20070213512A1 (en) *	2002-10-01	2007-09-13	Krafft Grant A	Amyloid beta peptide analogs and assemblies thereof
US8506959B2 (en)	2002-11-01	2013-08-13	Neotope Biosciences Limited	Prevention and treatment of synucleinopathic and amyloidogenic disease
US20080014194A1 (en)	2003-10-31	2008-01-17	Elan Pharmaceuticals, Inc.	Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8697082B2 (en)	2002-11-01	2014-04-15	Neotope Biosciences Limited	Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en)	2002-11-01	2005-03-16	Elan Pharm Inc	Prevention and treatment of synucleinopathic disease
US9034337B2 (en)	2003-10-31	2015-05-19	Prothena Biosciences Limited	Treatment and delay of outset of synucleinopathic and amyloidogenic disease
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
ATE468886T1 (de)	2003-02-10	2010-06-15	Applied Molecular Evolution	Abeta-bindende moleküle
US8663650B2 (en)	2003-02-21	2014-03-04	Ac Immune Sa	Methods and compositions comprising supramolecular constructs
ES2246177B1 (es) *	2003-05-08	2007-03-01	Universidad De Zaragoza.	Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
US7358331B2 (en)	2003-05-19	2008-04-15	Elan Pharmaceuticals, Inc.	Truncated fragments of alpha-synuclein in Lewy body disease
DK2361928T3 (en)	2003-05-19	2017-07-03	Prothena Biosciences Ltd	Truncated fragments of alpha synuclein in Lewy body disease
PE20050627A1 (es)	2003-05-30	2005-08-10	Wyeth Corp	Anticuerpos humanizados que reconocen el peptido beta amiloideo
US7807171B2 (en)	2003-07-25	2010-10-05	Ac Immune Sa	Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
WO2005047860A2 (fr)	2003-11-08	2005-05-26	Elan Pharmaceuticals, Inc.	Anticorps a l'alpha-synucleine
EP1717250A4 (fr) *	2004-02-20	2008-10-01	Immuno Biological Lab Co Ltd	Anticorps monoclonal et utilisation de celui-ci
SE0401601D0 (sv)	2004-06-21	2004-06-21	Bioarctic Neuroscience Ab	Protofibril specific antibodies and uses thereof
MX2007000998A (es)	2004-07-30	2007-07-11	Rinat Neuroscience Corp	Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
MX2007001679A (es)	2004-08-09	2007-05-23	Elan Pharm Inc	Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
EP1838854B1 (fr)	2004-12-15	2012-10-31	Janssen Alzheimer Immunotherapy	Anticorps reconnaissant le peptide beta amyloide
JP2008523815A (ja)	2004-12-15	2008-07-10	エランファーマインターナショナルリミテッド	認知の改善における使用のためのヒト化アミロイドβ抗体
GT200600031A (es)	2005-01-28	2006-08-29		Formulacion anticuerpo anti a beta
SI2289909T1 (sl) *	2005-11-30	2015-03-31	Abbvie Inc.	Presejalni postopek, postopek za ÄŤiĹˇÄŤenje nedifuzibilnih Abeta-oligomerov, selektivna protitelesa proti nedifuzibilnim Abeta-oligomerom in postopek za izdelavo protiteles
EP1976877B2 (fr)	2005-11-30	2016-10-05	AbbVie Inc.	Anticorps monoclonaux contre la protein beta-amyloide et utilisation de ceux-ci
CA2628703C (fr)	2005-11-30	2019-10-29	Abbott Laboratories	Anticorps anti-globulomere a.beta., fractions de liaison aux antigenes de ceux-ci, hydridomes , acides nucleiques, vecteurs, cellules hotes correspondants, procedes de production des anticorps, compositions comprenant les anticorps, utilisations des anticorps et procedes d'utilisation de ces anticorps
EP2004688B2 (fr)	2006-03-23	2014-03-05	BioArtic Neuroscience AB	Anticorps ameliores selectifs de protofibrilles et leur utilisation
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
JP2010504089A (ja) *	2006-09-25	2010-02-12	ユニフェルジテイト・マーストリヒト	心不全を発生させる危険がある被検者を診断および／または処置するための手段および方法
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
HRP20140049T1 (hr)	2007-01-05	2014-02-28	University Of Zürich	Anti beta-amiloid antitijela i njihova upotreba
ES2635317T3 (es)	2007-01-05	2017-10-03	University Of Zurich	Anticuerpo anti-beta-amiloide y sus usos
US8147833B2 (en)	2007-02-23	2012-04-03	Neotope Biosciences Limited	Prevention and treatment of synucleinopathic and amyloidogenic disease
EP2118300B1 (fr)	2007-02-23	2015-05-27	Prothena Biosciences Limited	Prévention et traitement de maladies synucléinopathiques et amyloïdogéniques
EP3067066B1 (fr)	2007-02-23	2019-03-27	Prothena Biosciences Limited	Prevention et traitement de la maladie synucleinopathique et amyloidogenique
EP2124952A2 (fr)	2007-02-27	2009-12-02	Abbott GmbH & Co. KG	Méthode de traitement d'amyloïdoses
US8003097B2 (en)	2007-04-18	2011-08-23	Janssen Alzheimer Immunotherapy	Treatment of cerebral amyloid angiopathy
TR201802286T4 (tr) *	2007-04-20	2018-03-21	The Chemo Sero Therapeutic Res Institute	Peptidle bağışıklık yanıtının arttırılması için yöntem.
PT2182983E (pt)	2007-07-27	2014-09-01	Janssen Alzheimer Immunotherap	Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
EP2175879A4 (fr) *	2007-08-09	2010-09-22	Sylvan Pharmaceuticals Pty Ltd	Traitement de maladies associées à la protéine prion
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
TR201901497T4 (tr)	2008-04-29	2019-02-21	Bioarctic Ab	Alfa-sinüklein ile ilişkili bozukluklar için terapötik ve teşhis yöntemlerinde kullanıma yönelik antikorlar ve aşılar.
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
CN102317316B (zh)	2008-12-19	2014-08-13	帕尼玛制药股份公司	人抗α突触核蛋白自身抗体
CN106397588B (zh)	2010-02-26	2020-09-08	生命北极神经科学公司	原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用
KR20110111594A (ko) *	2010-04-05	2011-10-12	서울대학교산학협력단	알파-시뉴클레인 유래 곱슬 아밀로이드 섬유의 제조방법, 이를 이용한 하이드로젤의 제조 방법 및 그 이용 방법
US8987419B2 (en)	2010-04-15	2015-03-24	AbbVie Deutschland GmbH & Co. KG	Amyloid-beta binding proteins
WO2011151833A1 (fr) *	2010-06-03	2011-12-08	Ramot At Tel-Aviv University Ltd.	Méthodes de traitement du diabète et compositions capables de traiter le diabète
CN102311499A (zh) *	2010-07-09	2012-01-11	博生吉医药科技(苏州)有限公司	一种癌症治疗用人源化单克隆抗体及其制备及应用
WO2012020124A1 (fr)	2010-08-12	2012-02-16	Ac Immune S.A.	Vaccin obtenu par génie génétique
MX358739B (es)	2010-08-14	2018-09-03	Abbvie Inc Star	Proteinas de union a amiloide beta.
AU2011322553B2 (en)	2010-10-26	2015-07-02	Ac Immune S.A.	Liposome-based construct comprising a peptide modified through hydrophobic moieties
CN105693865B (zh) *	2011-06-01	2020-07-17	厦门大学	包含白喉毒素无毒突变体crm197或其片段的融合蛋白
MX357193B (es)	2011-06-23	2018-06-29	Univ Zuerich	Moleculas de union anti-alfa sinucleina.
RS53496B1 (sr)	2011-10-04	2015-02-27	Affiris Ag	POSTUPAK ZA DETEKCIJU Aβ-SPECIFIČNIH ANTITELA U BIOLOŠKOM UZORKU
EP3865510A3 (fr)	2014-07-10	2021-10-27	BioArctic AB	Anticorps à liaison protofibrille a-bêta améliorée
CN105616405B (zh) *	2014-11-05	2021-05-07	中国人民解放军第三军医大学第三附属医院	依达拉奉在制备用于预防和治疗脑淀粉样血管病的药物中的应用
MA41115A (fr)	2014-12-02	2017-10-10	Biogen Int Neuroscience Gmbh	Procédé de traitement de la maladie d'alzheimer
US10464999B2 (en)	2015-01-28	2019-11-05	Prothena Biosciences Limited	Anti-transthyretin antibodies
US9879080B2 (en)	2015-01-28	2018-01-30	Prothena Biosciences Limited	Anti-transthyretin antibodies
US10633433B2 (en)	2015-01-28	2020-04-28	Prothena Biosciences Limited	Anti-transthyretin antibodies
EP3070096A1 (fr) *	2015-03-19	2016-09-21	Ludwig-Maximilians-Universität München	Peptide ou collection de peptides dérivés de protéine précurseur de l'amyloïde
JP7452829B2 (ja)	2015-11-09	2024-03-19	ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア	アミロイドベータのエピトープおよびそれに対する抗体
US10774120B2 (en) *	2015-11-09	2020-09-15	The University Of British Columbia	Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
CA3004482A1 (fr)	2015-11-09	2017-05-18	Neil R. Cashman	Epitopes n-terminaux dans la beta-amyloide et anticorps conformationnellement selectifs associes
US10265497B2 (en)	2015-11-24	2019-04-23	Massachusetts Institute Of Technology	Systems and methods for treating dementia
AU2017299858B2 (en)	2016-07-18	2024-07-25	Promis Neurosciences, Inc.	Antibodies to Amyloid beta
US20180125920A1 (en)	2016-11-09	2018-05-10	The University Of British Columbia	Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
KR102674264B1 (ko)	2016-11-17	2024-06-13	코그니토 쎄라퓨틱스, 인코포레이티드	시각 자극을 통한 신경 자극 방법 및 시스템
US11530257B2 (en)	2017-06-29	2022-12-20	The Trustees Of Columbia University In The City Of New York	Chimeric antibodies for treatment of amyloid deposition diseases
US12286469B2 (en)	2017-07-18	2025-04-29	The University Of British Columbia	Humanized antibodies binding to amyloid-beta (A-beta)
CA3070446A1 (fr)	2017-07-25	2019-01-31	Immutics, Inc.	Traitement du cancer par blocage de l'interaction de tim-3 et de son ligand
US11382974B2 (en) *	2017-08-01	2022-07-12	The Trustees Of Columbia University In The City Of New York	Methods and compositions for treatment of amyloid deposition diseases
EP3672631B9 (fr)	2017-08-22	2023-06-28	Biogen MA Inc.	Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
WO2019071206A1 (fr)	2017-10-06	2019-04-11	Prothena Biosciences Limited	Méthodes de détection de la transthyrétine
CN111315213B (zh)	2017-10-06	2023-09-12	普罗塞纳生物科学有限公司	抗甲状腺素运载蛋白抗体
US10960225B2 (en)	2017-10-10	2021-03-30	Massachusetts Institute Of Technology	Systems and methods for preventing, mitigating, and/or treating dementia via visual stimulation that binds higher order brain regions, reduces neurodegeneration and neuroinflammation, and improves cognitive function
WO2019074637A1 (fr)	2017-10-10	2019-04-18	Massachusetts Institute Of Technology	Systèmes et procédés de prévention, atténuation et/ou traitement de la démence
CN111433223B (zh)	2017-11-29	2024-08-27	诺和诺德A/S（股份有限公司）	抗甲状腺素运载蛋白单克隆抗体的冻干制剂
GB201720970D0 (en)	2017-12-15	2018-01-31	Ucb Biopharma Sprl	Antibodies
GB201720975D0 (en)	2017-12-15	2018-01-31	Ucb Biopharma Sprl	Anti-alpha synuclein antibodies
US12018069B2 (en)	2018-06-28	2024-06-25	The Trustees Of Columbia University In The City Of New York	Methods and compositions for imaging amyloid deposits
CN115359999A (zh)	2018-11-02	2022-11-18	台达电子企业管理（上海）有限公司	变压器模块及功率模块
WO2020094883A1 (fr) *	2018-11-09	2020-05-14	Neurimmune Ag	Modèle animal non humain de xénogreffe amyloïde dérivé d'un patient
WO2020160156A2 (fr)	2019-01-30	2020-08-06	Immutics, Inc.	Anticorps anti-gal3 et leurs utilisations
KR102135130B1 (ko) *	2019-02-15	2020-07-17	충북대학교 산학협력단	트랜스타이레틴 단백질에 특이적으로 결합하는 dna 앱타머 및 이의 용도
KR20230016186A (ko)	2020-05-26	2023-02-01	트루바인딩 아이엔씨.	갈렉틱-3 차단에 의한 염증성 질환의 치료 방법
EP4236988A4 (fr) *	2020-10-30	2024-10-30	Rush University Medical Center	Immunothérapie intranasale pour le traitement de la maladie d'alzheimer
CN115475247B (zh) *	2021-06-16	2024-02-20	厦门大学	β2-微球蛋白或其抑制剂的制药用途
CA3239708A1 (fr) *	2021-12-03	2023-06-08	Aubin MICHALON	Nouveau dosage de puissance pour des medicaments a base d'anticorps et moyens utiles associes
TWI824398B (zh) *	2022-01-27	2023-12-01	慈濟學校財團法人慈濟大學	一種肌動蛋白重組調節物之抑制劑用於製備治療睡眠剝奪引起之記憶退化之藥物之用途
CN120457342A (zh) *	2022-12-05	2025-08-08	神经免疫有限公司	环状化合物及环状化合物在用于检测抗体的测定中的用途

Family Cites Families (203)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US573547A (en) *		1896-12-22		smith
US73655A (en) *		1868-01-21		Improvement in safety-pockets
US14692A (en) *		1856-04-15		Improved diaphragm fluid-meter
CH652145A5 (de)	1982-01-22	1985-10-31	Sandoz Ag	Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4443427A (en) *	1982-06-21	1984-04-17	Sidney Farber Cancer Institute, Inc.	Monoclonal antibody
US4634666A (en)	1984-01-06	1987-01-06	The Board Of Trustees Of The Leland Stanford Junior University	Human-murine hybridoma fusion partner
US5208036A (en)	1985-01-07	1993-05-04	Syntex (U.S.A.) Inc.	N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4666829A (en)	1985-05-15	1987-05-19	University Of California	Polypeptide marker for Alzheimer's disease and its use for diagnosis
WO1987001597A1 (fr) *	1985-09-19	1987-04-26	Toray Industries, Inc.	COLONNE D'EXTRACTION DE beta2-MICROGLOBULINE
US4641473A (en) *	1985-12-23	1987-02-10	Trezza Ronald F	Clip construction for wall arrangement
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US5231170A (en)	1986-08-27	1993-07-27	Paul Averback	Antibodies to dense microspheres
GB8625435D0 (en) *	1986-10-23	1986-11-26	Erba Farmitalia	Human apolipoprotein ai
US5220013A (en)	1986-11-17	1993-06-15	Scios Nova Inc.	DNA sequence useful for the detection of Alzheimer's disease
US5187153A (en) *	1986-11-17	1993-02-16	Scios Nova Inc.	Methods of treatment using Alzheimer's amyloid polypeptide derivatives
US5290762A (en) *	1986-12-24	1994-03-01	John Lezdey	Treatment of inflammation
DE3702789A1 (de)	1987-01-30	1988-08-18	Bayer Ag	Vorlaeuferprotein des apc-polypeptids, dafuer codierende dna und diagnostische verwendung der dna und des proteins
EP0832981A1 (fr)	1987-02-17	1998-04-01	Pharming B.V.	Séquences d'ADN pour diriger des protéines vers les glandes mammaires, afin d'être secrétées efficacement
GB8720115D0 (en) *	1987-08-26	1987-09-30	Cooper G J S	Treatment of diabetes mellitus
US4883666A (en) *	1987-04-29	1989-11-28	Massachusetts Institute Of Technology	Controlled drug delivery system for treatment of neural disorders
US5229490A (en)	1987-05-06	1993-07-20	The Rockefeller University	Multiple antigen peptide system
US5583112A (en)	1987-05-29	1996-12-10	Cambridge Biotech Corporation	Saponin-antigen conjugates and the use thereof
US5057540A (en)	1987-05-29	1991-10-15	Cambridge Biotech Corporation	Saponin adjuvant
US5571499A (en)	1987-06-24	1996-11-05	Autoimmune, Inc.	Treatment of autoimmune diseases by aerosol administration of autoantigens
US5641474A (en) *	1987-06-24	1997-06-24	Autoimmune, Inc.	Prevention of autoimmune diseases by aerosol administration of autoantigens
US5849298A (en)	1987-06-24	1998-12-15	Autoimmune Inc.	Treatment of multiple sclerosis by oral administration of bovine myelin
US5869054A (en) *	1987-06-24	1999-02-09	Autoimmune Inc.	Treatment of multiple sclerosis by oral administration of autoantigens
AU632991B2 (en)	1987-06-24	1993-01-21	Autoimmune, Inc.	Treatment of autoimmune diseases by oral administration of autoantigens
US5571500A (en)	1987-06-24	1996-11-05	Autoimmune, Inc.	Treatment of autoimmune diseases through administration by inhalation of autoantigens
US5645820A (en) *	1987-06-24	1997-07-08	Autoimmune, Inc.	Treatment of autoimmune diseases by aerosol administration of autoantigens
US5004697A (en) *	1987-08-17	1991-04-02	Univ. Of Ca	Cationized antibodies for delivery through the blood-brain barrier
CA1339014C (fr)	1987-10-08	1997-03-25	Ronald E. Majocha	Anticorps pour peptide a4-amyloide
US5231000A (en)	1987-10-08	1993-07-27	The Mclean Hospital	Antibodies to A4 amyloid peptide
AU2728588A (en)	1987-10-23	1989-05-23	Genetics Institute Inc.	Composition and method for treating cancers characterized by over-expression of the c-fms proto-oncogene
US5266561A (en) *	1988-01-11	1993-11-30	Amylin Pharmaceuticals, Inc.	Treatment of type 2 diabetes mellitus
WO1989006689A1 (fr)	1988-01-13	1989-07-27	The Mclean Hospital Corporation	Constructions genetiques renfermant le gene amyloide cerebral d'alzheimer
US5785973A (en) *	1988-02-01	1998-07-28	Praxis Biologics, Inc.	Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
US4912094B1 (en)	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
ES2055785T3 (es)	1989-01-17	1994-09-01	Eniricerche Spa	Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas.
AU5525090A (en)	1989-04-14	1990-11-16	Research Foundation For Mental Hygiene, Inc.	Monoclonal antibody to amyloid peptide
AU5439790A (en)	1989-04-14	1990-11-16	Research Foundation For Mental Hygiene, Inc.	Cerebrovascular amyloid protein-specific monoclonal antibody sv17-6e10
HU212924B (en)	1989-05-25	1996-12-30	Chiron Corp	Adjuvant formulation comprising a submicron oil droplet emulsion
US5399346A (en)	1989-06-14	1995-03-21	The United States Of America As Represented By The Department Of Health And Human Services	Gene therapy
US5262303A (en) *	1989-10-13	1993-11-16	Trustees Of Boston University	Ligand/anti-ligand assays for adherent proteins
IT1237764B (it)	1989-11-10	1993-06-17	Eniricerche Spa	Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
US5633076A (en)	1989-12-01	1997-05-27	Pharming Bv	Method of producing a transgenic bovine or transgenic bovine embryo
EP0506785B1 (fr)	1989-12-20	2000-03-15	Autoimmune, Inc.	Traitement ameliore de maladies auto-immunes par administration par aerosol d'auto-antigenes
ES2284161T3 (es)	1990-01-12	2007-11-01	Amgen Fremont Inc.	Generacion de anticuerpos xenogenicos.
HUT61896A (en)	1990-03-02	1993-03-29	Autoimmune Inc	Process for producing orally administrable pharmaceutical compositions comprising autoantigenes, suitable for improving down-control of autoimmune diseases
US5279833A (en)	1990-04-04	1994-01-18	Yale University	Liposomal transfection of nucleic acids into animal cells
EP0451700A1 (fr)	1990-04-10	1991-10-16	Miles Inc.	Minigènes APP recombinants pour l'expression dans des souris transgéniques comme modèles de la maladie d'Alzheimer
US5264618A (en)	1990-04-19	1993-11-23	Vical, Inc.	Cationic lipids for intracellular delivery of biologically active molecules
EP0527823A1 (fr)	1990-04-24	1993-02-24	The Regents Of The University Of California	Purification, detection et procedes d'utilisation de protease nexine-2
US5753624A (en)	1990-04-27	1998-05-19	Milkhaus Laboratory, Inc.	Materials and methods for treatment of plaquing disease
EP0526511B1 (fr)	1990-04-27	1997-05-28	MCMICHAEL, John	Procede et composition servant a traiter des etats pathologiques du systeme nerveux central associes a la proteine beta amyloide anormale
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
AU8081491A (en)	1990-06-01	1991-12-31	Cetus Corporation	Compositions and methods for identifying biologically active molecules
US5593970A (en)	1990-06-11	1997-01-14	Biochem Pharma Inc.	Heterocyclic anthracycline analogs
JPH06507782A (ja)	1990-06-15	1994-09-08	サイオス　ノバ　インコーポレイテッド	アルツハイマー病のアミロイド形成開症状を示すヒト以外の組換え哺乳動物
CA2109602C (fr)	1990-07-10	2002-10-01	Gregory P. Winter	Methodes de production de membres de paires de liaison specifiques
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5780587A (en) *	1990-08-24	1998-07-14	President And Fellows Of Harvard College	Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
US5874299A (en)	1990-08-29	1999-02-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de)	1990-08-29	2006-01-05	GenPharm International, Inc., Palo Alto	Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en)	1990-08-29	1998-08-04	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
WO1993012227A1 (fr)	1991-12-17	1993-06-24	Genpharm International, Inc.	Animaux transgeniques non humains capables de produire des anticorps heterologues
US5877397A (en)	1990-08-29	1999-03-02	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
NZ239643A (en) *	1990-09-17	1996-05-28	North American Vaccine Inc	Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
CA2092823A1 (fr)	1990-09-28	1992-03-29	Barry D. Greenberg	Animaux transgeniques ayant un gene precurseur amyloide de la maladie d'alzheimer
ATE319474T1 (de)	1990-10-15	2006-03-15	Autoimmune Inc	Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
CA2372251A1 (fr)	1991-01-21	1992-08-06	Michael John Mullan	Test et modele pour la maladie d'alzheimer
US5192753A (en) *	1991-04-23	1993-03-09	Mcgeer Patrick L	Anti-rheumatoid arthritic drugs in the treatment of dementia
US5871907A (en)	1991-05-15	1999-02-16	Medical Research Council	Methods for producing members of specific binding pairs
US5858657A (en)	1992-05-15	1999-01-12	Medical Research Council	Methods for producing members of specific binding pairs
DE122004000008I1 (de)	1991-06-14	2005-06-09	Genentech Inc	Humanisierter Heregulin Antikörper.
US5672805A (en)	1991-07-18	1997-09-30	The Regents Of The University Of California	Transgenic mice expressing the neurotoxic C-terminus of β-amyloid precursor protein
US5434050A (en) *	1991-08-13	1995-07-18	Regents Of The University Of Minnesota	Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
US5283185A (en)	1991-08-28	1994-02-01	University Of Tennessee Research Corporation	Method for delivering nucleic acids into cells
US5770358A (en)	1991-09-18	1998-06-23	Affymax Technologies N.V.	Tagged synthetic oligomer libraries
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
DK0620849T3 (da)	1992-01-07	2003-10-20	Elan Pharm Inc	Transgene dyremodeller for Alzheimer's sygdom
US5679348A (en) *	1992-02-03	1997-10-21	Cedars-Sinai Medical Center	Immunotherapy for recurrent HSV infections
EP0625910B1 (fr)	1992-02-11	2003-07-23	Henry M. Jackson Foundation For The Advancement Of Military Medicine	Structure immunogene a double vecteur
US5314813A (en)	1992-02-19	1994-05-24	Scripps Research Institute	Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines
DE69332518T2 (de)	1992-02-28	2003-09-04	Autoimmune Inc	Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung
DK0640131T3 (da) *	1992-03-17	1999-11-01	Novartis Ag	Gensplejsere antistoffer
EP0561087B1 (fr)	1992-03-20	1999-08-04	N.V. Innogenetics S.A.	Forme mutée du gène de la protéine du précurseur beta-amyloide
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
US5441870A (en)	1992-04-15	1995-08-15	Athena Neurosciences, Inc.	Methods for monitoring cellular processing of β-amyloid precursor protein
US5604102A (en)	1992-04-15	1997-02-18	Athena Neurosciences, Inc.	Methods of screening for β-amyloid peptide production inhibitors
GB9209118D0 (en)	1992-04-28	1992-06-10	Sb 120 Amsterdam Bv	Vaccine compositions
US5837672A (en)	1992-07-10	1998-11-17	Athena Neurosciences, Inc.	Methods and compositions for the detection of soluble β-amyloid peptide
US5766846A (en) *	1992-07-10	1998-06-16	Athena Neurosciences	Methods of screening for compounds which inhibit soluble β-amyloid peptide production
WO1994001772A1 (fr)	1992-07-13	1994-01-20	The Children's Medical Center Corporation	CRIBLAGE DE TRAITEMENTS DE LA MALADIE D'ALZHEIMER SUR LA BASE DE LA PRODUCTION DE β-AMYLOIDE
EP0863211A1 (fr)	1992-07-31	1998-09-09	Medeva Holdings B.V.	Expression de protéines recombinantes fusionnées dans des bactéries attenuées
US5958883A (en) *	1992-09-23	1999-09-28	Board Of Regents Of The University Of Washington Office Of Technology	Animal models of human amyloidoses
DE69333087T2 (de)	1992-10-01	2004-05-06	The Trustees Of Columbia University In The City Of New York	Komplexe kombinatorische chemische banken, die mit markierungen versehen sind
US5605811A (en)	1992-10-26	1997-02-25	Athena Neurosciences, Inc.	Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
DE69333144T2 (de) *	1992-10-26	2004-05-19	Elan Pharmaceuticals, Inc., San Francisco	Verfahren zur Identifizierung von Hemmstoffe der Produktion des beta-Amyloidpeptids
US5674703A (en)	1992-12-02	1997-10-07	Woo; Savio L. C.	Episomal vector systems and related methods
DE69329974T2 (de)	1992-12-04	2001-07-19	Medical Research Council, London	Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
EP0683234B2 (fr)	1993-01-25	2007-06-06	Takeda Chemical Industries, Ltd.	Anticorps dirige contre le beta-amyloide ou un derive de ce dernier et son utilisation
US5955317A (en) *	1993-01-25	1999-09-21	Takeda Chemical Industries, Ltd.	Antibodies to β-amyloids or their derivatives and use thereof
CA2115900A1 (fr)	1993-02-22	1994-08-23	Gerald W. Becker	Cribles pharmaceutiques et anticorps
CN1087176C (zh)	1993-03-23	2002-07-10	史密斯克莱·比奇曼生物公司	含有3－o脱酰基单磷酰脂a的疫苗制剂
US5643562A (en) *	1993-03-29	1997-07-01	Queen's University Of Kingston	Method for treating amyloidosis
ES2180576T3 (es) *	1993-04-27	2003-02-16	United Biomedical Inc	Construcciones peptidicas de lhrh inmunogenicas y estimuladores de inmunidad universales sinteticos para vacunas.
WO1994028412A1 (fr)	1993-05-28	1994-12-08	The Miriam Hospital	Composition et procede d'imagerie in vivo de depots d'amyloide
CA2168459C (fr)	1993-07-30	2002-10-01	Mohammed Anjam Khan	Proteines de fusion contenant le c-terminal de la toxine du tetanos liee a une proteine heterologue
EP0666566B1 (fr) *	1993-08-10	2001-11-14	Sony Corporation	Enregistreur-lecteur
US5728385A (en) *	1993-08-12	1998-03-17	Classen Immunotherapies, Inc.	Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae
WO1995005853A1 (fr)	1993-08-26	1995-03-02	The Regents Of The University Of California	Procede, compositions et dispositifs pour l'administration de polynucleotides nus qui codent des peptides a activite biologique
ES2318848T3 (es)	1993-09-14	2009-05-01	Pharmexa Inc.	Peptidos que se unen a pan dr para potenciar la respuesta inmunitaria.
US5446650A (en)	1993-10-12	1995-08-29	Tektronix, Inc.	Logic signal extraction
EP0728215B1 (fr)	1993-10-20	2002-02-20	Duke University	PROCEDE DE LIAISON D'UN ELEMENT AU PEPTIDE Beta-AMYLOIDE
BR9407947A (pt)	1993-11-02	1996-11-26	Affymax Tech Nv	Processo para sintetizar moléculas diversas em uma pluralidade de substratos e uma coleçao molecular etiquetade para realizaçao reaçoes de copulaçao em contas em paralelo para triar uma coleçao molecular etiquetada para detectar a presença de um ou mais diferentes etiquetas e para determinar a sequência de síntese aparelho para reaçoes de copulaçao paralelas em suportes sólidos bloco de alinhamento ótico para uso com um detector ótico sistemas de distribuiçao para distribuir reagentes dispositiv
US5744368A (en)	1993-11-04	1998-04-28	Research Foundation Of State University Of New York	Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
US5827690A (en)	1993-12-20	1998-10-27	Genzyme Transgenics Corporatiion	Transgenic production of antibodies in milk
GB9326253D0 (en)	1993-12-23	1994-02-23	Smithkline Beecham Biolog	Vaccines
US5434170A (en) *	1993-12-23	1995-07-18	Andrulis Pharmaceuticals Corp.	Method for treating neurocognitive disorders
US5914349A (en)	1994-01-10	1999-06-22	Teva Pharmaceutical Industries, Ltd.	Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
ATE278023T1 (de) *	1994-01-27	2004-10-15	Univ Minnesota	Nicht humane, transgenische säugetiere mit sich entwickelnder neurologischer krankheit
US5877399A (en) *	1994-01-27	1999-03-02	Johns Hopkins University	Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
WO1995020979A1 (fr) *	1994-02-03	1995-08-10	The Picower Institute For Medical Research	Compositions et procedes de modulation de l'amyloidose induite par des produits terminaux de glycosylation avancee
JPH10500112A (ja)	1994-05-06	1998-01-06	ファーマコピーア，インコーポレイテッド	組合せジヒドロベンゾピランライブラリー
WO1995031996A1 (fr) *	1994-05-25	1995-11-30	Milkhaus Lab	Compositions et procedes de traitement de maladies a formation de plaque
US5505947A (en)	1994-05-27	1996-04-09	The University Of North Carolina At Chapel Hill	Attenuating mutations in Venezuelan Equine Encephalitis virus
US5622701A (en)	1994-06-14	1997-04-22	Protein Design Labs, Inc.	Cross-reacting monoclonal antibodies specific for E- and P-selectin
US5663046A (en)	1994-06-22	1997-09-02	Pharmacopeia, Inc.	Synthesis of combinatorial libraries
US6417178B1 (en)	1994-07-19	2002-07-09	University Of Pittsburgh	Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits
US6114133A (en)	1994-11-14	2000-09-05	Elan Pharmaceuticals, Inc.	Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US5688651A (en)	1994-12-16	1997-11-18	Ramot University Authority For Applied Research And Development Ltd.	Prevention of protein aggregation
US5786180A (en)	1995-02-14	1998-07-28	Bayer Corporation	Monoclonal antibody 369.2B specific for β A4 peptide
CA2214247C (fr) *	1995-03-14	2004-02-10	Praecis Pharmaceuticals Incorporated	Modulateurs de l'agregation de substances amyloides
US7153510B1 (en)	1995-05-04	2006-12-26	Yale University	Recombinant vesiculoviruses and their uses
DE19518147B4 (de) *	1995-05-17	2013-09-05	Günther Nath	UV-stabiler Flüssigkeitslichtleiter
WO1996039176A1 (fr)	1995-06-05	1996-12-12	Brigham & Women's Hospital	Utilisation de la tolerance orale pour supprimer les reponses immunitaires de th1 et de th2 et pour supprimer la production d'anticorps
US5948763A (en) *	1995-06-07	1999-09-07	New York University	Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
ES2174027T3 (es) *	1995-06-30	2002-11-01	American Cyanamid Co	Composiciones estables que contienen macrolidos y macrolidos combinados con unas vacunas.
US5671500A (en) *	1995-08-07	1997-09-30	Balk; Brett	Overhead door spring shield system
WO1997006809A1 (fr)	1995-08-21	1997-02-27	Cytrx Corporation	Compositions et procedes pour la stimulation de la croissance
JP3713074B2 (ja)	1995-08-30	2005-11-02	栄研化学株式会社	血清アミロイドａを認識するモノクローナル抗体
WO1997010505A1 (fr) *	1995-09-14	1997-03-20	The Regents Of The University Of California	ANTICORPS SPECIFIQUE DU PrPSc NATIF
US5750361A (en)	1995-11-02	1998-05-12	The Regents Of The University Of California	Formation and use of prion protein (PRP) complexes
WO1997017614A1 (fr)	1995-11-10	1997-05-15	Elan Corporation, Plc	Peptides accroissant le transport dans les tissus et procedes d'identification et d'utilisation correspondants
AU1072897A (en)	1995-12-12	1997-07-03	Karolinska Innovations Ab	Peptide binding the klvff-sequence of amyloid beta
JPH09178743A (ja)	1995-12-27	1997-07-11	Oriental Yeast Co Ltd	可溶性ａｐｐの定量法
US6150091A (en) *	1996-03-06	2000-11-21	Baylor College Of Medicine	Direct molecular diagnosis of Friedreich ataxia
JP4229341B2 (ja)	1996-03-23	2009-02-25	財団法人阪大微生物病研究会	破傷風毒素の機能的フラグメント抗原及び破傷風ワクチン
CA2183901A1 (fr)	1996-08-22	1998-02-23	Johanna E. Bergmann	Cibles pour le traitement et le diagnostic de la maladie d'alzheimer et du syndrome de down chez les humains
US6057367A (en) *	1996-08-30	2000-05-02	Duke University	Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
US6797495B2 (en) *	1996-11-05	2004-09-28	The Regents Of The University Of California	Somatic cells with ablated PrP gene and methods of use
ATE441432T1 (de)	1997-03-10	2009-09-15	Ottawa Hospital Res Inst	Verwendung von nicht-methyliertem cpg dinukleotid in kombination mit aluminium als adjuvantien
CN1138579C (zh)	1997-03-31	2004-02-18	阿尔萨公司	可扩散植入的释放系统
PT994728E (pt) *	1997-04-09	2008-11-11	Intellect Neurosciences Inc	Anticorpos recombinantes específicos contra terminações beta-amilóide, codificação por adn e métodos de utilização destes
US8173127B2 (en) *	1997-04-09	2012-05-08	Intellect Neurosciences, Inc.	Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US5972269A (en)	1997-06-17	1999-10-26	Taurus International Manufacturing, Inc.	Method of forming cavities in ceramic or metal injection molded parts using a fugitive core
WO1999000150A2 (fr)	1997-06-27	1999-01-07	Regents Of The University Of California	Ciblage d'un medicament radiopharmaceutique peptidique utilisant in vivo la barriere hemato-encephalique d'un primate et un anticorps monoclonal dirige contre le recepteur humain de l'insuline
IT1293511B1 (it)	1997-07-30	1999-03-01	Gentili Ist Spa	Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
US7078191B1 (en)	1997-08-01	2006-07-18	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation
US6004925A (en) *	1997-09-29	1999-12-21	J. L. Dasseux	Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6923964B1 (en) *	1997-12-02	2005-08-02	Neuralab Limited	Active immunization of AScr for prion disorders
US7964192B1 (en) *	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
TWI239847B (en) *	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
TR200001596T2 (tr)	1997-12-03	2000-12-21	Fujisawa Pharmaceutical Co., Ltd.	Yumuşak hap ilaç ve bunun üretim usulü
JP2002511385A (ja)	1997-12-03	2002-04-16	ニューララブリミテッド	アルツハイマー病におけるβ−アミロイド関連変化を抑制する方法
FR2777015B3 (fr)	1998-02-23	2000-09-15	Financ De Biotechnologie	Procede et moyens pour l'obtention de modeles cellulaires et animaux de maladies neurodegeneratives
NO314086B1 (no)	1998-05-08	2003-01-27	Gemvax As	Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
JP2003532618A (ja)	1998-05-19	2003-11-05	イエダリサーチアンドデベロプメントカンパニイリミテッド	細胞、神経系−特異的抗原およびそれらの用途
US20030147882A1 (en)	1998-05-21	2003-08-07	Alan Solomon	Methods for amyloid removal using anti-amyloid antibodies
WO1999060024A1 (fr)	1998-05-21	1999-11-25	The University Of Tennessee Research Corporation	Procede d'elimination d'amyloide a l'aide d'anticorps anti-amyloide
DE69915697T2 (de)	1999-01-19	2005-01-13	Pharmacia & Upjohn Co., Kalamazoo	Packungsverfahren für Oxidationsempfindliche Medikamente
JP2002535289A (ja) *	1999-01-22	2002-10-22	ドウアリング，マシユー・ジヨン	神経疾患のワクチン媒介治療
AR024558A1 (es)	1999-06-01	2002-10-16	Neuralab Ltd	Composiciones del peptido a-beta y procesos para producir las mismas
UA81216C2 (en)	1999-06-01	2007-12-25		Prevention and treatment of amyloid disease
JP5249482B2 (ja)	1999-06-16	2013-07-31	ボストン・バイオメデイカル・リサーチ・インステイテユート	インビボのβ−アミロイドレベルの免疫学的制御
US6294171B2 (en)	1999-09-14	2001-09-25	Milkhaus Laboratory, Inc.	Methods for treating disease states comprising administration of low levels of antibodies
AU784312B2 (en)	1999-11-29	2006-03-09	Bellus Health (International) Limited	Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
CN1414976A (zh)	1999-12-08	2003-04-30	明德塞特生物制药(美国)公司	作为免疫原的嵌合肽及其抗体,以及利用嵌合肽或抗体进行免疫的方法
EE200200444A (et)	2000-02-21	2003-12-15	Pharmexa A/S	Meetod autoloogse beeta-amüloidvaigu in vivo mahasurumiseks, amüloidogeense polüpeptiidi analoog, seda kodeeriv nukleiinhappefragment ning kasutamineimmunogeense kompositsiooni valmistamiseks
KR100767146B1 (ko)	2000-02-24	2007-10-15	워싱톤 유니버시티	Ａβ 펩티드를 격리시키는 인간화 항체
CA2404237C (fr)	2000-04-05	2010-01-26	University Of Tennessee Research Corporation	Techniques d'etude, de diagnostic et de traitement d'amylose
CA2408925A1 (fr)	2000-05-22	2001-11-29	New York University	Peptides immunogenes synthetiques mais non-amyloidogenes homologues de beta-amyloide, destines a induire une reaction immunitaire contre les peptides beta-amyloide et les depots amyloides
WO2002003911A2 (fr)	2000-07-07	2002-01-17	Lars Lannfelt	Prevention et traitement de la maladie d'alzheimer
EP1172378A1 (fr)	2000-07-12	2002-01-16	Richard Dr. Dodel	Anticorps humains anti-beta-amyloid et leur utilisation pour le traitement de la maladie d'Alzheimer
US20020009445A1 (en) *	2000-07-12	2002-01-24	Yansheng Du	Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
IT1319277B1 (it)	2000-10-24	2003-09-26	Chiesi Farma Spa	Proteine di fusione utili per il trattamento di immunizzazione dellamalattia di alzheimer.
IL139308A0 (en)	2000-10-26	2001-11-25	Marikovsky Moshe	Peptides from amyloid precursor protein which inhibit tumor growth and metastasis
WO2002060920A2 (fr) *	2000-12-27	2002-08-08	Board Of Regents, University Of Texas System	Isomeres de prion, procede de preparation et composition contenant des isomeres de prion
US20020147882A1 (en) *	2001-04-10	2002-10-10	Pua Khein Seng	Universal serial bus flash memory storage device
EP1251138B1 (fr) *	2001-04-19	2006-07-26	Hermann Dr. Schätzl	Dimères de prions comme vaccin
AU2002345843A1 (en) *	2001-06-22	2003-01-08	Panacea Pharmaceuticals, Inc.	Compositions and methods for preventing protein aggregation in neurodegenerative diseases
ES2435741T3 (es) *	2001-08-06	2013-12-23	Kao Corporation	Composición acondicionadora
JP2006508045A (ja) *	2002-07-30	2006-03-09	エスペリオンセラピューティクス，インコーポレイテッド	ヒト以外の動物のアポリポプロテインａ−ｉタンパク質の使用方法
WO2010033861A1 (fr) *	2008-09-18	2010-03-25	Cedars-Sinai Medical Center	Procédé optique pour la détection de la maladie d'alzheimer

2000
- 2000-01-06 UA UA2001118223A patent/UA81216C2/uk unknown
- 2000-06-01 EA EA200101250A patent/EA200101250A1/ru unknown
- 2000-06-01 CN CNA2007101032809A patent/CN101091795A/zh active Pending
- 2000-06-01 ES ES10182493.6T patent/ES2445799T3/es not_active Expired - Lifetime
- 2000-06-01 DE DE60045550T patent/DE60045550D1/de not_active Expired - Lifetime
- 2000-06-01 PT PT00938075T patent/PT1185296E/pt unknown
- 2000-06-01 BR BR0011103-1A patent/BR0011103A/pt not_active Application Discontinuation
- 2000-06-01 ES ES00938075T patent/ES2362029T3/es not_active Expired - Lifetime
- 2000-06-01 MX MXPA01012293A patent/MXPA01012293A/es active IP Right Grant
- 2000-06-01 NZ NZ556622A patent/NZ556622A/en not_active IP Right Cessation
- 2000-06-01 SG SG200401386-8A patent/SG147275A1/en unknown
- 2000-06-01 IL IL14656300A patent/IL146563A0/xx unknown
- 2000-06-01 AT AT00938075T patent/ATE495755T1/de active
- 2000-06-01 CA CA2375104A patent/CA2375104C/fr not_active Expired - Fee Related
- 2000-06-01 KR KR1020107019313A patent/KR101142772B1/ko not_active Expired - Lifetime
- 2000-06-01 HU HU0201205A patent/HU229986B1/hu unknown
- 2000-06-01 EP EP00938075A patent/EP1185296B1/fr not_active Expired - Lifetime
- 2000-06-01 EE EEP200100645A patent/EE05492B1/xx unknown
- 2000-06-01 WO PCT/US2000/015239 patent/WO2000072876A2/fr not_active Ceased
- 2000-06-01 HK HK02106697.1A patent/HK1045117B/en not_active IP Right Cessation
- 2000-06-01 SK SK1718-2001A patent/SK288207B6/sk not_active IP Right Cessation
- 2000-06-01 PL PL352717A patent/PL202217B1/pl unknown
- 2000-06-01 SG SG200401385-0A patent/SG147274A1/en unknown
- 2000-06-01 CZ CZ20014154A patent/CZ302971B6/cs not_active IP Right Cessation
- 2000-06-01 CN CN00808358A patent/CN1377278A/zh active Pending
- 2000-06-01 TR TR2001/03469T patent/TR200103469T2/xx unknown
- 2000-06-01 NZ NZ587223A patent/NZ587223A/en not_active IP Right Cessation
- 2000-06-01 HR HR20010893A patent/HRP20010893A2/hr not_active Application Discontinuation
- 2000-06-01 AU AU53163/00A patent/AU5316300A/en not_active Abandoned
- 2000-06-01 KR KR1020097012115A patent/KR20090071673A/ko not_active Withdrawn
- 2000-06-01 KR KR1020017015508A patent/KR100930559B1/ko not_active Expired - Lifetime
- 2000-06-01 EP EP10182493.6A patent/EP2364719B1/fr not_active Expired - Lifetime
2001
- 2001-11-19 IL IL146563A patent/IL146563A/en not_active IP Right Cessation
- 2001-11-21 IS IS6170A patent/IS2925B/is unknown
- 2001-11-23 BG BG106140A patent/BG65756B1/bg unknown
- 2001-11-23 ZA ZA200109662A patent/ZA200109662B/en unknown
- 2001-11-26 NO NO20015758A patent/NO20015758L/no not_active Application Discontinuation
2007
- 2007-08-20 US US11/842,046 patent/US7977316B2/en not_active Expired - Fee Related
- 2007-08-20 US US11/842,052 patent/US8124081B2/en not_active Expired - Fee Related
2009
- 2009-03-13 US US12/403,414 patent/US20090285822A1/en not_active Abandoned
- 2009-03-30 US US12/414,347 patent/US20090285809A1/en not_active Abandoned
2010
- 2010-07-22 IL IL207166A patent/IL207166A/en not_active IP Right Cessation
- 2010-11-05 US US12/940,750 patent/US20110064734A1/en not_active Abandoned
2011
- 2011-02-23 US US13/033,336 patent/US20110177066A1/en not_active Abandoned
- 2011-02-23 US US13/033,418 patent/US20110182893A1/en not_active Abandoned
- 2011-04-18 US US13/088,983 patent/US20110287049A1/en not_active Abandoned
- 2011-04-19 CY CY20111100403T patent/CY1111639T1/el unknown

Also Published As

Publication number	Publication date
HK1160392A1 (en)	2012-08-17
CN1377278A (zh)	2002-10-30
HU229986B1 (en)	2015-04-28
IL146563A0 (en)	2002-07-25
US20110182893A1 (en)	2011-07-28
AU5316300A (en)	2000-12-18
EE05492B1 (et)	2011-12-15
HUP0201205A3 (en)	2004-07-28
NZ587223A (en)	2011-12-22
IL146563A (en)	2010-11-30
WO2000072876A3 (fr)	2001-05-03
US20110287049A1 (en)	2011-11-24
CZ20014154A3 (cs)	2002-11-13
CA2375104A1 (fr)	2000-12-07
KR20100099355A (ko)	2010-09-10
IS6170A (is)	2001-11-21
CA2375104C (fr)	2013-12-24
HK1045117B (en)	2011-08-05
CZ302971B6 (cs)	2012-01-25
BG106140A (bg)	2002-08-30
US20080248023A1 (en)	2008-10-09
CN101091795A (zh)	2007-12-26
WO2000072876A2 (fr)	2000-12-07
SK288207B6 (sk)	2014-07-02
EP2364719A1 (fr)	2011-09-14
KR20090071673A (ko)	2009-07-01
DE60045550D1 (de)	2011-03-03
NZ556622A (en)	2009-03-31
NO20015758L (no)	2002-01-30
US20110177066A1 (en)	2011-07-21
HUP0201205A2 (en)	2002-08-28
IL207166A (en)	2013-11-28
ZA200109662B (en)	2003-05-23
HK1045117A1 (en)	2002-11-15
US7977316B2 (en)	2011-07-12
US20110064734A1 (en)	2011-03-17
EP1185296B1 (fr)	2011-01-19
ES2362029T3 (es)	2011-06-27
SG147274A1 (en)	2008-11-28
BR0011103A (pt)	2002-03-19
KR100930559B1 (ko)	2009-12-09
ATE495755T1 (de)	2011-02-15
TR200103469T2 (tr)	2002-05-21
EP2364719B1 (fr)	2013-11-13
CY1111639T1 (el)	2015-10-07
PL352717A1 (en)	2003-09-08
PL202217B1 (pl)	2009-06-30
EE200100645A (et)	2003-02-17
BG65756B1 (bg)	2009-10-30
ES2445799T3 (es)	2014-03-05
KR101142772B1 (ko)	2012-05-18
US8124081B2 (en)	2012-02-28
SG147275A1 (en)	2008-11-28
IS2925B (is)	2015-06-15
EA200101250A1 (ru)	2002-06-27
US20090285822A1 (en)	2009-11-19
SK17182001A3 (sk)	2002-09-10
KR20020025884A (ko)	2002-04-04
EP1185296A2 (fr)	2002-03-13
MXPA01012293A (es)	2002-11-07
US20080248029A1 (en)	2008-10-09
HRP20010893A2 (en)	2003-04-30
PT1185296E (pt)	2011-04-19
US20090285809A1 (en)	2009-11-19
NO20015758D0 (no)	2001-11-26
IL207166A0 (en)	2010-12-30

Publication	Publication Date	Title
UA81216C2 (en)	2007-12-25	Prevention and treatment of amyloid disease
US6913745B1 (en)	2005-07-05	Passive immunization of Alzheimer's disease
US6923964B1 (en)	2005-08-02	Active immunization of AScr for prion disorders
BG106241A (bg)	2002-08-30	Метод за профилактика и лечение на амилоидогенно заболяване
EA009283B1 (ru)	2007-12-28	Предупреждение и лечение амилоидогенного заболевания
AU2005202644B2 (en)	2009-03-05	Prevention and treatment of amyloidogenic disease
JP2003516929A (ja)	2003-05-20	アミロイド形成性疾患の予防および治療
HK1160392B (en)	2014-07-18	Determination of the prognosis of a patient undergoing treatment for alzheimer's disease
JP2012102131A (ja)	2012-05-31	アミロイド形成性疾患の予防および治療